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GENERAL INTRODUCTION
Epidemiology of heart failure
Nearly 180.000 Dutch have heart failure (HF) today, with an increasing incidence 
approaching 125 per 100.000 population among persons older than 55 years of 
age1. It is a major public health problem leading to frequent hospitalisation and 
increased mortality.
HF is a clinical syndrome arising from diverse causes that impair the ability of the 
heart to function as a pump. Most patients with the condition have poorly 
contracting ventricles and a low ventricular ejection fraction. HF is usually resulting 
from multiple long-standing cardiovascular abnormalities, such as coronary artery 
disease or hypertension2. Many have uncorrected valvular disease, such as aortic 
stenosis or mitral regurgitation, or abnormal filling resulting in diastolic HF3. 
Patients frequently complain of fatigue, breathlessness and chest pain. These 
presenting symptoms impair exercise capacity and restrict ability to perform 
physical activities. There are consequences for work, leisure, social activities and 
for mood. To grade the clinical severity of HF physicians often use the New York 
Heart Association (NYHA) classification that places patients in one of four 
categories based on how much they are limited during physical activity (I: No 
symptoms and no limitation in ordinary physical activity, II: Mild symptoms and 
slight limitation during ordinary activity, III: Marked limitation in activity due to 
symptoms, even during less-than-ordinary activity, IV: Severe limitations and 
symptoms even while at rest)4. The clinical diagnosis of HF can be supported by 
cardiac imaging, which can rapidly provide detailed information about the structure 
and function of the cardiac chambers and valves. The left ventricular ejection 
fraction (LVEF) is such an index of cardiac function that can be measured with 
echocardiography. 
A majority of patients with chronic HF are elderly with an incidence of the condition 
nearly doubling each decade after the age of 405.
Accordingly, substantial efforts have been made to identify and treat the factors 
that predict prognosis and recurrent hospitalisation. End points of rehabilitation 
programs and controlled studies now include the effect of the studied intervention 
on quality of life and the rate of hospital admissions. Although innovations in 
treatment of patients with HF have reduced mortality, symptomatic HF continues to 
confer a worse prognosis than the majority of other chronic illnesses, with a one 
year mortality of approximately 45 percent6. 
Cognitive impairment in patients with heart failure
Both chronic heart failure and cognitive impairment are common problems in the 
aging western population. Although normal aging is not necessarily associated with 
diminished cognitive function, many older patients experience at least mild to 
moderate decrease in memory function and mental speed. A large proportion of 
patients who have cognitive impairment do not fulfil the diagnostic criteria for 
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dementia. This “mild cognitive impairment” is twice as common as dementia, 
occurring in 17% of the population over the age of 65 years7. 
While the emergence of such common conditions as chronic HF and cognitive 
impairment may occur by chance within the same individuals, there is an 
increasing body of evidence to suggest that HF is independently associated with 
cognitive impairment.
HF has been proposed as a possible cause of cognitive impairment since 1977, 
expressed by the term “cardiogenic dementia” 8. The limited number of studies that 
have systematically assessed cognitive performance in HF patients found that 
memory, slowed psychomotor speed and attention deficits are the most frequently 
occurring impairments in these patients9;10.
The variability of the reported prevalence rates for cognitive impairment in previous 
studies can probably be explained by both differences in characteristics of the 
samples of predominantly younger patients awaiting cardiac transplantation or the 
older patients hospitalised for HF and the differences in the sensitivity and 
specificity of the neuropsychological instruments used. The relation with 
cardiovascular parameters (e.g. LVEF and blood pressure) is inconsistent and has 
consequently led to varying pathophysiological assumptions11;12.
The importance of detecting cognitive deficits is stressed by several reports. 
Among older patients with HF for instance, cognitive impairment, even when 
subclinical, has been independently associated with increased 1-year mortality and 
with increased probability of functional disability13;14. Furthermore, management of 
HF involves complex pharmacological therapy, diet and fluid restrictions, monitored 
physical activity and patient education. The complexity of these regimens can be 
difficult for patients to understand, remember and manage. Failure to follow a 
rehabilitation program can result in exacerbation of symptoms, which in turn results 
in higher admission rates. Multidisciplinary management programs and introduction 
of self-care strategies can prevent readmissions, thereby reducing health care 
utilisation and improving quality of life15;16. For cognitive impaired HF patients, the 
complex treatment of symptoms and the need for lifestyle modification is 
challenging. Knowledge of the extent and specific nature of the cognitive deficits in 
these patients could help clinicians make informed decisions in developing an 
individual treatment regime. 
Pathophysiological mechanisms
The variety of co-morbidity that contributes to the development of cognitive decline 
in patients with HF make the underlying pathophysiological mechanisms difficult to 
identify.
Common vascular risk factors like hypertension, diabetes mellitus, 
hypercholesterolemia and atrial fibrillation that contribute to the development of HF 
are also known to be related to an increased risk of cognitive impairment and 
dementia.17 Moreover, approximately 20% of all cases of dementia are 
predominantly vascular in etiology and many of the remainder (mainly Alzheimer 
disease) have a vascular component. Coronary artery disease, atrial fibrillation and 
hypertension have all been reported to be associated with impairment in such 
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specific cognitive domains as verbal learning, abstract thinking and attention.18;19 In 
patients with chronic HF, however, the association of cognitive impairment has 
been shown to be independent of the presence of atrial fibrillation and 
hypertension. While they may be a contributing factor, these cardiovascular risk 
factors are not likely to be the sole explanation. 
It is probable that impairment of cerebral circulation plays an important role in the 
mechanisms by which chronic HF affects cognitive performance. Both chronic 
cerebral hypoperfusion due to left ventricular dysfunction and multiple cardiogenic 
emboli have been suggested to cause of the observed cognitive deficits. In HF 
patients, lower-left ventricular ejection fraction is the most important predictor of 
risk for cerebral infarction and ventricular thrombus formation.20;21 While 
arrhythmias, valvulopathies and heart-wall disorders are potential sources of 
cerebral emboli, chronic hypoperfusion may lead to low grade ischemia of the deep 
white matter and possibly cerebral atrophy22. In order to identify plausible causative 
associations, silent cerebral infarction, white matter disease and eventually atrophy 
of cerebral structures that are related to specific cognitive functions (e.g. medial 
temporal lobe) need systematic investigation in this patient group.
Finally, common conditions in chronically ill patients that cause significant 
functional limitations like depression and extreme fatigue have also been linked to 
cognitive dysfunction, but still need further evaluation.23
Neuroimaging
The association between cerebral abnormalities on magnetic resonance imaging 
(MRI) and the presence of vascular risk factors has been investigated in different 
populations, and results have varied widely. Data obtained from large 
epidemiological MRI-studies indicate that increased white matter hyperintensities, 
lacunar infarcts and decreased brain volume are associated with increased risk for 
mild cognitive impairment17;24, though the specific contribution of each 
neuroimaging index to cognitive dysfunction remains less well-defined. In addition, 
while many studies have identified relationships between cognitive impairment and 
cardiovascular risk factors like hypertension25 and atrial fibrillation26, fewer studies 
have examined the relationship among specific indices of cardiac status and 
neuroimaging or cognitive status. Although it has been suggested that 
cardiovascular disease leading to HF imposes a high risk for various 
cerebrovascular complications, most of the previous reports in literature using MRI 
of the brain were descriptive in design and were mainly conducted in stroke 
patients or subjects with dementia. The epidemiological population based studies 
identify risk factors for cerebral white matter disease and dementia but they were 
not designed to investigate the prevalence and type of cerebrovascular disease in 
HF patients, without clinical evidence of stroke or dementia. Only three studies 
have previously investigated structural brain abnormalities among HF patients in 
relation to parameters of cardiac function27-29. However, the small sample size in 
these reports and various methods used for rating cerebral morphology limit 
interpretation of their results. Thus far, the role of cerebrovascular disease in 
cognitive impairment that often accompanies HF remains unclear.
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Aims and outline of this thesis
The aim of the thesis was to investigate the profile of cognitive impairment in 
independently living outpatients with chronic HF and to evaluate its association with 
structural abnormalities of the brain in relation to clinical and cardiovascular 
parameters. We hypothesized that HF was indepedently associated with specific 
cognitive deficits consisting of subcortical cerebral functions (e.g. executive 
functions and mental psychomotor speed), that in turn could be related to disease 
severity and structural abnormalities of the brain, measured by MRI-scanning. 
Moreover, we expected that HF was associated with decreased CBF-V, and that 
this reduction was associated with both neuropsychological deficits and 
cerebrovascular abnormalities, such as WMH.
In chapter 2 we performed a systematic review of the available literature to 
evaluate the results of systematic studies on the relationship between cognitive 
deterioration and HF. The purpose was to review these results critically and identify 
the shortcomings of previous studies. Finally we recommend priority areas for 
further research.
In chapter 3 the cognitive profile of the patients was assessed using an extensive 
neuropsychological battery, including tests of mental speed, executive functions, 
memory, language and visuospatial functions. By the use of a case-control design, 
comparing HF-patients to patients with the same cardiovascular risk profile but no 
evidence of HF and healthy controls we aimed to establish HF as the major 
discriminator between groups as a probable cause of cognitive impairment. 
In chapter 4 we used brain magnetic resonance imaging (MRI) to determine 
frequency and pattern of specific MRI abnormalities in outpatients with chronic HF, 
and to identify its demographic and clinical correlates. The associations between 
structural cerebral abnormalities on MRI and the presence of vascular risk factors 
were compared between a sample of 58 HF patients, 48 controls diagnosed with 
cardiovascular disease uncomplicated by HF (cardiac controls) and 42 healthy 
controls. Deep, periventricular and total white matter hyperintensities (WMH),  
lacunar and cortical infarcts, global and medial temporal lobe atrophy (MTA) were 
investigated.
Chapter 5 addresses the relationship of cognitive performance to cerebral 
abnormalities on neuroimaging in 58 non-demented outpatients with HF. 
Correlations between MRI-parameters and the cognitive measures, including tests 
of mental speed, executive functions, memory, language and visuospatial 
functions, were calculated.
In chapter 6 we evaluated the cerebral blood flow velocity of the middle cerebral 
artery, measured by TCD in a group of patients with chronic HF, cardiac controls 
and healthy individuals in order to analyse its relationship to cognitive performance 
and MRI abnormalities of the brain. 
In chapter 7 we summarize the main findings of the study and discuss the results in 
the light of our hypothesis. We conclude with suggestions for future research in the 
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field of possible causal mechanisms underlying cognitive impairment in HF and 
provide recommendations for clinical practice.
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ABSTRACT
Background
Heart failure (HF) and cognitive impairment are common medical conditions that 
are becoming increasingly prevalent in the ageing Western population. They are 
associated with frequent hospitalisation and increased mortality, particularly when 
they occur simultaneously. Evidence from a number of studies suggests that HF is 
independently associated with impairment in various cognitive domains.
Aims
This systematic literature review evaluates the relation between cognitive 
deterioration and HF.
Methods
We searched electronic databases from 1966 to May 2006 for studies that 
investigated cognitive function in HF patients. Twenty-two controlled studies that 
met the inclusion criteria were selected for analysis. Study characteristics and data 
on global cognitive performance, memory scores, psychomotor speed and 
depression scores were extracted and analysed using the Cochrane Review 
Manager software.
Results
Pooled analysis shows diminished neuropsychological performance in HF patients, 
as compared to control subjects. In a pooled sample of 2937 heart-failure patients 
and 14848 control subjects, the odds ratio for cognitive impairment was 1.62 (95% 
confidence interval:1.48-1.79, p<0.0001) among subjects with HF.
Conclusion
This review confirms the relationship between HF and cognitive impairment, but it 
also stresses the need for additional systematic neuropsychological data and 
adequate neuro-imaging from representative populations of HF patients.
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INTRODUCTION
The clinical syndrome of heart failure (HF) is an increasingly important and 
frequent complication of most diseases that affect the heart. It is one of the leading 
causes of hospitalisation, morbidity and mortality in Western countries, with a 
reported incidence of 1-2%.1-5 The prevalence of chronic HF is estimated to be ten 
percent among those over the age of 75, rising to 15-20% among the elderly 
population over the age of 80.6 Due to the aging population in Western countries, 
the prevalence of HF is expected to double within the next forty years. Some 
authors even predict that it will become the epidemic of the near future7.
Since 1977, HF has been proposed as a possible cause of cognitive dysfunction, 
expressed by the term ‘cardiogenic dementia’.8 In the past three decades, 
however, only a limited number of clinical studies have systematically assessed 
cognitive performance in HF patients. Although cognitive impairment or dementia 
may coincide with chronic HF for some individuals, an increasing body of evidence 
suggests that decreased heart function, as measured by indices of low cardiac 
output, is independently associated with impairment in various cognitive 
domains.9;10 The prevalence of mild cognitive impairment (MCI) exceeds the 
prevalence of dementia, ranging from 53% to 58% in older patients with mild to 
moderate HF.11 MCI is a general term most commonly used to describe a subtle 
but measurable deficit in one or multiple cognitive domains, most often memory. 
These deficits are greater than normally expected with aging, but a person does 
not show other symptoms of dementia, such as impaired judgment or reasoning 
and difficulties in performing activities of daily living. In the majority of cases it 
represents a transitional state between the cognitive changes of aging and the 
earliest clinical manifestations of dementia.12
Cognitive dysfunction has been reported in patients who suffer from a variety of 
cardiovascular disorders. It is well documented among hypertensive patients, after 
coronary artery bypass graft (CABG) surgery13-16 and among the survivors of 
sudden cardiac arrest.17 Because of the heterogeneity in reported samples of HF 
patients, where a variety of vascular risk factors and co-morbidity contribute to the 
development of cognitive decline, the underlying pathophysiological mechanisms 
are difficult to identify and yet unknown. Common conditions in chronically ill 
patients that cause significant functional limitations like depression and extreme 
fatigue have been linked to cognitive dysfunction, but still need further evaluation in 
this patient group.18
Although the documentation of neuropsychological changes in patients who are 
affected by HF has been recognised as an increasingly important feature in the 
development of treatment regimes for individual patients, there is still no generally 
accepted guideline for cognitive screening in HF patients.
We performed a literature review to evaluate the results of systematic studies on 
the relationship between cognitive deterioration and HF. The purpose of this article 
is to review these results critically and identify the shortcomings of previous 
studies. Finally we recommend priority areas for further research.
Chapter 2
18
METHODS
Search strategy and selection criteria
We used MEDLINE, the National Research Register, Embase (1980-2006, OVID 
online) and the Cochrane Controlled Trials Register of the Cochrane Library 
(edition 2002, no. 4) to search for studies that investigated the relationship 
between HF and cognition, and which were published between 1966 and May 
2006. The search included the following key words: heart failure, congestive; 
cognitive impairment, dysfunction, deficit; neuropsychological functions; cardiac 
transplantation; neuro-imaging, magnetic resonance imaging. In addition, we 
manually scanned the bibliographies of the articles that were found in the 
electronic search to identify studies that met our inclusion criteria.
Inclusion criteria
We included in our analysis only those studies that met the following criteria: 1) 
they addressed randomised clinical trials or case-control surveys designed to 
investigate the association between HF and cognitive impairment; 2) they 
assessed cognitive function using validated neuropsychological methods. These 
methods include a range of standardised neuropsychological tests and rating 
scales that have either age-corrected or age-and educationally corrected normative 
data in the investigated population; 3) the reported data were suitable for analysis; 
4) they were published in English.
Studies were evaluated according to their methods of investigation, data collection, 
sample characteristics, neuropsychological measures and interpretation of 
outcomes. Pathophysiological mechanisms causing cognitive impairment in HF 
patients in relation to diagnostic tests of cardiovascular and brain functions (e.g., 
brain imaging) were of particular interest, as they may point out directions for future 
research. Although not a formal neuropsychological measure, depression scores 
were also included in this review. Depressive symptoms are known to be an 
important confounder on neuropsychological functioning in patients affected by 
fatigue, breathlessness and angina all of which cause discomfort and disability. 
Especially in patients with HF, quality of life is compromised by these physical 
complications of chronic illness and emotional distress resulting from poor 
prognosis.19;20
Data analysis
Data were analysed using the Review Manager 4.2 software (Cochrane 
Collaboration). Mean scores and standardised deviations were extracted from the 
reviewed articles. Standardised mean difference (SMD) was calculated for 
proportions (fixed-effect model) using the Mantel-Haenszel method. To increase 
the homogeneity of the calculated results, the cognitive measures that were most 
commonly used to describe impairment in general cognitive functioning received 
priority. SMD was calculated for Mini-mental state examination (MMSE) scores, 
memory scores, Trail-making test (TMT)–A scores and depression-index scores. 
To adjust for heterogeneity among the neuropsychological methods that the 
studies had used to measure memory, a hierarchical approach was used in which 
total memory scores had precedence over delayed-memory scores, which 
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subsequently had precedence over immediate-recall scores. The studies that 
presented data for prevalence of cognitive impairment in HF patients and control 
subjects were used to calculate odds ratios (OR).
RESULTS
The search generated a list of fifty-seven studies that investigated cognitive 
impairment in HF patients. An additional six articles were identified for the review 
by scanning the reference lists of these studies. Only twenty-two of these sixty-
three articles met the inclusion criteria.
Methodology
No randomised controlled trials were identified in the literature. The majority (n=22 
studies) were categorised as case-control studies. Eight cohort studies21-30 and 
twenty-six cross-sectional studies18;31-41, including fourteen descriptive studies with 
correlational design11;42-53 were found. The latter group of uncontrolled studies was 
excluded because of statistical weakness and increased risk of sampling bias. Four 
studies54-57 did not provide raw data for analysis. Three studies published data that 
had already been analysed in previous publications.43;58;59 Characteristics of the 
studies that were ultimately included in the review are summarised in Table 1.
Sample characteristics
Total sample sizes including control groups ranged from 17 patients60;61 to 13635 
(1583 patients, 12052 controls).62 In four studies, the control groups consisted of 
healthy participants, both matched and unmatched.63-66 Patients with other cardiac 
diagnoses were used as controls in six studies.9;67-71 In six studies, patient groups 
were differentiated according to New York Heart Association (NYHA) functional 
class, MMSE or left ventricular ejection fraction (LVEF).9;11;60;72-74 In five studies, 
patients served as their own controls after cardiac transplant.64;75-78 Two studies62;79
used hospitalised patients with other diagnoses as controls.
Mean ages in these studies ranged from 38 (+/- 4.7) to 83 years (+/- 5.4). Overall, 
the groups that were investigated in the studies were heterogeneous and consisted 
primarily of hospitalised patients whose clinical state of HF was either sub-acute or 
stable.
In the transplant studies, data were analysed retrospectively, with the exception of 
Strauss and colleagues,70 who prospectively compared post-cardiac transplant 
patients with post-CABG patients. Three64;75;78 of the five transplant-study articles 
reported times of data collection. The data-collection methods that were reported in 
the remaining seventeen studies were either prospective, concerning consecutive 
patients prior to or during the intervention phase of a clinical trial, or cross-sectional 
over periods ranging from four months to more than three years.
Neuropsychological measures
All of the reports used standardised neuropsychological tests to determine 
cognitive outcomes. The MMSE was used as a screening measure for global 
cognitive performance in nine studies9;61;64;67-69;73;77;80 and it was the sole 
neuropsychological component in two of these articles.69;73 Ekman and 
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colleagues73 dichotomised the MMSE score, using a median value of 28 as a cut-
off at baseline to examine correlated variables in a HF population. The other 
authors used comparisons between means of MMSE or a cut-off score of 24 as 
indication of cognitive impairment.
Two authors62;79 used the Hodkinson Abbreviated Mental Test (AMT). This ten-item 
general cognitive screening test is comparative to the MMSE, and it was not 
designed to assess specific domains. Although these general screening tests for 
cognitive function offer the benefits of brevity and ease of administration, the single 
scores that they produce can mask mild impairments in specific cognitive domains.
The cognitive areas that were the most commonly assessed in the reviewed 
studies were memory, attention, problem solving and motor speed. Immediate 
reproduction and delayed recall of verbal (word lists), visual (figures) and auditory 
stimuli (short stories, sounds) were the most commonly applied methods of 
assessing memory. A number of the test batteries used recognition, semantic 
clustering and learning curves assessed by verbal-learning tests in addition to 
recall. Fourteen studies assessed simple and complex attention. Executive 
functions (planning, tactual performance, problem solving) were registered in 
eleven articles.61;63;65;68;70;72;74-78 These functions were most commonly assessed 
indirectly, using the TMT A/B or similar neurological tests. Motor speed, dexterity 
and reaction times were registered with both computerised and manual tests in 
thirteen studies.61;63-66;68;70;72;74-78 Pre-morbid intelligence was fully assessed in only 
eight studies, and it was partially assessed in two studies; the Wechsler Adult 
Intelligence Scale (WAIS) and National Adult Reading Test (NART) were the 
primary means of assessment.
The prevalence of anxiety and depression among HF patients is high,81;82 and 
these conditions affect scores on neuropsychological tests negatively. Eleven 
studies9;64;66-72;76;77 obtained results from mood and anxiety questionnaires and 
related these outcomes to cognitive function. The most commonly applied 
instruments are self-report rating inventories, measuring characteristic attitudes of 
depression. The Geriatric depression scales (GDS) was used in three studies9;67;69, 
the Beck’s Depression Inventory (BDI) in two studies70;77 and the Minnesota 
Multiphasic Personality Inventory (MMPI) in another two.75;76 The remaining four 
articles used less common scales for objective measurement of mood and anxiety, 
like the Rand’s Mental Health Inventory (MHI)72 and the Hospital anxiety and 
depression questionnaire (HAD).71
Neuro-physiological and neuro-anatomical measures
The only studies to perform brain imaging were conducted by Schmidt66 and by 
Alves and colleagues.61 Although this method can provide valuable information on 
pathophysiological mechanisms involved in neuro-cognitive functioning, no 
systematic visualisation of cerebral structures in HF patients had been performed, 
even in the cross-sectional studies that were excluded from this review. In two of 
the studies,64;70 electroencephalography (EEG), auditory and visually evoked 
potentials were used in conjunction with standardised neuropsychological tests.
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Cardiovascular parameters
All but six of the twenty-two reviewed studies reported parameters of 
cardiovascular function. The most common measures were LVEF, NYHA functional 
class, systolic and diastolic blood pressures.
Outcomes
Results of memory scores were suitable for analysis in thirteen studies, as 
described in Figure 1. The pooled sample in a total of 863 patients and 753 
controls shows a SMD of –0.43 in favour of the controls and patients who had 
received transplants, as compared to the HF patients. Only three65;74;78 of the 
studies that are presented contained references to standardised normative data for 
these tests. Because the remaining studies did not provide this information the 
prevalence and severity data were not interpretable.
Figure 1. Memory scores
Data on MMSE mean scores and standard deviations were available in six of nine 
studies that used the MMSE for global cognitive screening. Figure 2 indicates that 
HF is associated with a significant decrease in MMSE scores with a SMD of –0.32 
(n = 822 patients and 1578 controls). Cacciatore and colleagues69 reported the 
most dramatic finding in this group of studies; they found a two-fold increase in the 
risk of cognitive impairment among patients with HF (OR: 1.96; 95% confidence 
interval 1.07-3.58; p<0.028). This association was independent of age, education, 
gender, depression, alcohol consumption, smoking, atrial fibrillation, blood 
pressure and heart rate. Neither this study nor the Italian population study 
performed by Zuccala and colleagues provided raw data from the MMSE scores 
that could be used for pooled analysis.
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Figure 2. MMSE scores
The TMT-A, which measures attention, perceptual speed, cognitive flexibility and 
visual memory was used in nine articles. Data were suitable for pooled analysis in 
eight of these studies (total number of subjects = 466 patients and 469 healthy 
control subjects or transplant patients who served as their own controls). Results 
are shown in Figure 3. Overall, the performance of the HF patients in these studies 
on psychomotor tasks was worse than that of the control subjects.
Figure 3. Trailmaking test-A scores
Data on other cognitive domains that were frequently assessed were not suitable 
for pooled analysis.
The reported prevalence of cognitive impairment in HF patients ranged from 25%71
to 74%.78 Odds ratios were calculated when data for prevalence of cognitive 
impairment were available in the HF and control groups. Results are shown in 
Figure 4. The scores on neuropsychological tests used to calculate the OR were as 
follows: the MMSE in the studies conducted by Cacciatore, Almeida and Trojano; 
the Hodkinson mental test in the study by Zuccala and Corsonello; the Rey 
Auditory Verbal Learning Test in the study by Roman; and global-memory scores 
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from the articles by Strauss and Grubb. The pooled OR was calculated as 1.62 
(95% confidence interval: 1.48-1.79). The risk of cognitive impairment (i.e., global 
cognitive and memory deterioration) in this pooled sample of 2937 HF patients and 
14848 control subjects was therefore 1.62 times greater for HF patients than it was 
for control subjects.
Figure 4. Odds ratio for cognitive impairment
The prevalence of depression in hospitalised elderly patients with HF is estimated 
to be approximately 36%, as compared to 25% in patients without heart disease.81
Major depression has been reported to be a strong predictor of second myocardial 
infarction, and it is a risk factor for increased mortality, particularly for HF patients.83
Although depressed mood may produce deterioration in cognitive performance in 
general, it was assessed in only eleven of the twenty-two studies reviewed. Nine 
studies9;66;67;69;71;72;75-77 found that depression was more prevalent among HF 
patients as compared to control subjects. Only Strauss and colleagues70 described 
no differences in mood and anxiety. Five studies9;69;71;72;76 conducted correlation 
analyses between depression scores and cognitive performance to examine 
potential effects on neuropsychological test outcomes. In their logistic regression 
analysis, Trojano and colleagues9 found that depression was an independent 
correlate of abnormal performance on at least three neuropsychological tests, with 
an OR of 2.36 (95% CI=1.54-3.66). In contrast, the results of Grimm and 
colleagues64 could not confirm this relation. In the remaining four articles, cognitive 
outcomes were corrected for depression scores. The most frequently reported 
symptoms were depressed mood and feelings of incapacity, fatigue and weakness 
during work and other activities. Results of pooled analysis are shown in Figure 5. 
A pooled SMD of 0.48 (95%, CI 0.39-0.57, Z=10.13, p<0.00001) was calculated for 
depression scores in 1081 patients in favour of 1713 control subjects.
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Figure 5. Depression scores
Neurophysiological and neuro-anatomical measures
Schmidt and colleagues compared the MRI brain scans and neuropsychological 
performance of twenty neurologically asymptomatic patients (mean age = 40 +/-
7.8 years) who were suffering from idiopathic dilated cardiomyopathy to those of 
twenty age-matched control subjects. The patients exhibited a significantly higher 
rate of cerebral infarcts (20% versus 0%, p<0.05) and cortical and ventricular 
atrophy than controls. Furthermore, patients with abnormal MRI findings had 
significantly poorer cognitive performance on learning tasks, verbal memory and 
reaction times than did the healthy control participants, who were matched for age 
and education. Alves and colleagues61 detected a higher incidence of regional 
cerebral blood flow reductions, bilaterally in the cuneus and the posterior cortical 
areas of the brain among HF patients than among control subjects, but they found 
no significant differences between the white-matter hyper-intensities on the MRI 
brain scans of ten HF patients and those of fourteen control subjects.
Strauss and colleagues70 reported that 55% of the forty heart transplant candidates 
had abnormal EEG findings, but they did not relate these findings to the results of 
their neuropsychological outcomes.
Cardiovascular parameters
Cacciatore and colleagues69 analysed systolic and diastolic blood pressure in 
patients, stratified by NYHA-class and MMSE-score and adjusted for age and 
education. Their study showed that systolic blood-pressure reduction was 
negatively associated with HF only among cognitively impaired patients 
(MMSE<24). Diastolic blood pressure variables could not predict cognitive 
impairment. Zuccala and colleagues62 also found a significant negative association 
between systolic blood pressure and the prevalence of cognitive impairment 
among older HF patients (MMSE<24). Systolic blood-pressure levels below 
130mmHg predicted lower MMSE scores, but only among patients with HF. These 
results are confirmed in the recent population-based cohort study by Qui and 
colleagues.80 No consistent association between other cardiovascular risk factors 
and cognitive impairment could be proven in the reviewed studies. Only 
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Nussbaum60 and Almeida68 found that low LVEF was a significant predicting risk 
factor for worse scores on neuropsychological tests. In contrast, five 
authors63;65;72;73;76 were unable to confirm this association.
Reversibility of cognitive impairment linked to severity of illness
Most of the studies that related the severity of cardiac failure to neuropsychological 
performance suggest that cognitive deficits become more prominent with 
increasing severity of illness. In contrast to Schall and colleagues,78 who found that 
cardiac transplantation fails to improve postoperative cognitive skills significantly, 
four authors64;75-77 reported significant improvement in the cognitive functioning 
(e.g., memory) of patients who had received transplants. Deshields and 
colleagues77 reported that this improvement was independent of significant 
decreases in depression and anxiety. Although the samples were limited, 
reversibility of cognitive impairment is suggested by these results.
DISCUSSION
The results of this review indicate that HF is associated with a pattern of 
generalised cognitive impairment that includes primarily memory, attention, mental 
flexibility and global cognitive deficits. Pooled analysis shows diminished 
neuropsychological performance, as expressed by significant differences in SMD 
rates for MMSE scores, memory scores and psychomotor speed/attention when 
comparing HF patients to control subjects. The data also suggest that depression 
is more prevalent among HF patients. Although some results are contradictory, 
depressed mood and anxiety are independently correlated with deterioration in 
cognitive performance in this patient sample. The systematic neuropsychologic 
assessment in HF patients is therefore fundamental to disclose conditions 
potentially favoring the onset of cognitive impairment such as depression.
The variability of the prevalence rates for cognitive impairment that are reported in 
the reviewed studies can probably be explained by both differences in 
characteristics of the samples of predominantly younger patients awaiting cardiac 
transplantation or the older patients hospitalised for HF and the differences in the 
range and specificity of the instruments used to assess cognitive impairment. The 
heterogeneity of samples, including patients and control subjects who had prior 
histories of stroke and brain injury, poses an additional limitation on the samples in 
most of the studies. Moreover, the applicability of identical cut-off scores for some 
of the neuropsychological measures among older individuals has been the subject 
of debate, and the influence of age differences on test results therefore remains. In 
the Italian population studies9;62;67;69;79, cognitive performance was frequently 
assessed among older hospitalised patients shortly after admission. In the sub-
acute stage of heart disease, such environmental and disease-related factors as 
dyspnoea and pain are known to lower scores on neuropsychological tests84, and 
they could therefore partially explain the high prevalence of cognitive impairment 
among these patients. On the other hand, the global neuropsychological screening 
methods that were used are known to underestimate mental dysfunction, due to 
their non-specific sensitivity to disturbances in various cognitive domains. The 
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differences in the breadth and specificity of the instruments used to assess 
cognitive impairment and their influence on the results is best illustrated by the 
study from Almeida and Tamai.68 They reported that 54% of the HF population in 
their study had MMSE scores <24 and 73,5% had total Cambridge Cognition 
Examination (CAMCOG) scores of <80, which is used as a cut-off score for 
cognitive impairment. This in contrast to the older control participants, that had 
prevalence rates for impairment of 33% and 30% respectively. One explanation for 
the discrepancy between the prevalence of cognitive impairment in the same 
patient sample can be found in the characteristics of the test and their validated 
cut-off scores. The CAMCOG is a standardised, more extensive cognitive battery 
for the diagnosis of mental disorders in the elderly. It covers more domains than 
the MMSE and evaluates eleven subscales including orientation, language, 
memory, learning, attention, praxis, abstract thinking and perception. The 
sensitivity and specificity of CAMCOG are higher than the MMSE for the DSM-III 
diagnoses of dementia, since it manifests a smoother gradient of cognitive 
assessment, while MMSE tends to manifest polarized results.85 As a result the 
prevalence of cognitive impairment may be underestimated in studies that used the 
MMSE, or a comparable test like the AMT, as the only neuropsychological 
measure, when compared to studies using more comprehensive 
neuropsychological instruments.
A number9;62;67-69;72-74 of the reviewed studies that investigated cognitive function in 
relation to cardiovascular disease and cardiac surgery did not present analyses 
according to etiologic groups. Conclusions based on information from single 
diagnostic groups or aggregate categories of heterogeneous diagnoses are difficult 
to evaluate. They might reflect cognitive disorders after CABG surgery in an 
ischemic cardiomyopathy subgroup that can be related to cardio-embolic 
complications of surgery. A meta-analysis of 176 studies involving 205717 post-
CABG patients identified an elevated frequency of non-fatal stroke among 
postoperative patients.86 In addition, patients whose cognitive function declines 
immediately after surgery (approximately fifty percent of patients who undergo 
CABG) are at increased risk for long-term cognitive decline and a reduced level of 
overall cognitive functioning.87 Most of the reviewed studies did not take these high 
rates of prevalence into account in either the analysis or the pathophysiological 
assumptions concerning the subgroups that were investigated.
Pathophysiological considerations
Practically all of the reviewed studies discuss two important pathophysiological 
hypotheses; cerebral hypo-perfusion and multiple cardiogenic emboli. Because 
they may occur together, it may be difficult to determine which of these conditions 
causes impaired cognition in patients with HF. The cerebral effects of chronic 
reductions in cardiac output, as observed in chronic HF patients, remains poorly 
understood. It is important to note that this cerebral malfunction has proven 
reversible after correction of cardiac output in heart-transplant patients. This 
suggests that the cause of ‘cardiogenic dementia’ is treatable for some patients. 
Recent evidence supports the hypothesis that, in addition to HF subjects, chronic 
hypotension or excessive antihypertensive treatment also pose an increased risk of 
developing dementia.80;88 Besides cerebral hypo-perfusion, cardiogenic embolism 
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is an important factor. Arrhythmias, valvulopathies and heart-wall disorders are 
potential sources of cerebral emboli, but it is unlikely to be the sole explanation for 
cerebral malfunction.
Ischemic heart disease and hypertension are the main causes of HF. Other 
cardiovascular risk factors (e.g., atrial fibrillation and diabetes mellitus) that 
contribute to the development of HF are also associated with lower scores on 
cognitive tests. Indeed, coronary artery disease, atrial fibrillation, hypertension and 
diabetes have all been reported to be associated with impairment in such specific 
cognitive domains as verbal  learning, abstract thinking and attention.89;90 In 
patients with chronic HF, however, the association of cognitive impairment has 
been shown to be independent of the presence of atrial fibrillation and 
hypertension; while it may be a contributing factor, it is not the sole explanation. On 
the other hand, these vascular risk factors are known to be related to cerebral 
white-matter lesions and an increased risk of dementia.91 Data derived from the 
Rotterdam study indicate that these lesions are independently associated with a 
history of stroke or myocardial infarction, and they tend to be associated with lower 
scores on cognitive tests.
In our opinion, when describing the neuropsychological effects of cardiovascular 
disease on the brain, no conclusion can be drawn about the pathophysiological 
mechanisms without further assessing cerebral function in relation to structural 
abnormalities. Vascular damage (e.g., white-matter lesions) caused by
cardiovascular risk factors could eventually be the cause of mental deterioration in 
patients with HF, rather than HF itself. Without adequate radiological visualisation 
of the brain, this remains a tentative association. Only two studies61;66 used 
magnetic resonance scanning of the brain. These scans revealed that HF patients 
with idiopathic and ischemic cardiomyopathy demonstrated significantly worse 
cognitive test performance than did control subjects. Schmidt observed that 
performance was most impaired in patients who suffered from morphologic 
cerebral abnormalities (primarily cerebral infarcts and atrophy).66
It is important to note that various biochemical and physiological perturbations, 
often side effects of medicines used to treat cardiovascular disease, can affect the 
brain globally, often affecting the most complex intellectual functions first.92 This is 
further demonstrated by another factor that is associated with cognitive dysfunction 
and dementia, the apolipoprotein E (APOE) epsilon4 allele; this factor has been a 
topic of increasing attention. Recent studies indicate that the risk of substantial 
decline in cognitive function among the elderly may be modified by gene-
environment interactions between APOE genotype and cardiovascular risk 
factors.93;94
Eventually not the heart, but a common pathophysiological pathway that affects the 
microcirculation in both the heart and the brain could be responsible for the 
observed mental deficits. Heart-failure patients, therefore, might be generally more 
susceptible than control subjects are to vascular damage caused by such 
cardiovascular risk factors as hypertension, diabetes and smoking.
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The identification of a treatable cause for cognitive impairment could have major 
implications and allows the development of an appropriate treatment regime. As 
previously described significant improvement in cognitive function among patients 
who have received heart transplants has frequently been reported. In addition, the 
implantation of pacemakers has had positive effects on both the cardiac and 
verbal-cognitive functioning of elderly bradycardic patients.95 More recently, 
Zuccala and colleagues observed that the use of ACE inhibitors among HF patients 
is associated with improving cognition (OR=1.57; 95% CI 1.18-2.08); this result has 
also emerged in multivariable regression modelling, independent of blood-pressure 
levels at baseline or discharge.54 Mental deficits may therefore be at least partially 
reversible following clinical treatment.
Implications for future research
The research conducted to date has largely been limited to male transplant 
candidates and elderly hospitalised populations that include primarily women or 
population-based HF cohorts. Future research should make more use of broad 
neuropsychological assessment data and adequate neuro-imaging from 
representative populations of HF patients, including outpatients. To direct future 
research and clinical practice, studies are needed that investigate cognitive 
function using extensive batteries that include executive functions in HF, in order to 
categorise profile, prevalence and severity in the various etiological subgroups, 
with respect to underlying pathophysiological mechanisms. Most clinical 
neuropsychological tests measure memory, language, intelligence and perceptual 
abilities, and they were not designed to identify substantial deficits in executive 
functions. As an important subset of cognitive functions, executive functions enable 
humans to develop and carry out plans, solve problems, function in social 
structures, adapt to unexpected circumstances, form analogies and enable 
reasoning; they also ensure that memories can be retrieved. Deficits in executive 
functions can have devastating effects on medical self-management and quality of 
life. Neuropsychological tests that are designed to assess this important cognitive 
domain are under-valued in the reviewed studies.
CONCLUSION
Preserving cognitive function and quality of life within the growing population of 
elderly HF patients requires an awareness of this cerebrovascular complication in 
the early stages of heart disease. Although systematic data on cognitive status in 
HF patients is becoming increasingly available, it is clear that there is need for 
prospective studies and experimental models to clarify the pathogenesis of this 
condition further, with special attention to cerebral morphologic abnormalities in the 
various etiologic subgroups of HF patients. Neuropsychology should be used to 
specify a cognitive profile; the assessment of executive functions is indispensable 
in this regard.
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ABSTRACT
Objective
To determine the frequency and pattern of cognitive dysfunction in outpatients with 
chronic congestive heart failure (HF), and to identify the corresponding 
demographic and clinical correlates.
Design
Case-control study.
Setting and participants
A sample of 62 HF outpatients, 53 controls diagnosed with cardiovascular disease 
uncomplicated by HF (cardiac controls) and 42 healthy controls were investigated.
Measurements
Neuropsychological assessment included tests of mental speed, executive 
functions, memory, language and visuospatial functions. Composite z-scores for 
five cognitive domains as well as mean z-score for overall cognitive performance 
were computed. The cut-off score to indicate cognitive impairment was defined as 
the overall healthy participants’ cognitive z-score minus 2 standard deviations. 
Independent demographic and clinical predictors of cognitive impairment were 
identified using linear regression analysis.
Results
Compared to healthy controls, HF patients showed a pattern of general cognitive 
impairment, including impairment of executive functions, memory, language, 
mental speed and attention. 25% (p=.041) of HF patients were classified as 
cognitively impaired, in comparison to 15% of the cardiac controls and 4% of the 
healthy controls. Independent predictors of cognitive impairment in HF patients 
were: estimated intelligence, NYHA-class and presence of the apolipoprotein E-4 
allele. 
Conclusion
Cognitive dysfunction is relatively common in HF patients with deficits being most 
prominent in the domains of executive functions, memory, language and mental 
speed. Disease severity and ApoE genotype are likely to be important 
determinants for cognitive impairment in chronic HF patients. 
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INTRODUCTION
Congestive heart failure (HF) and cognitive impairment are common medical 
conditions increasingly more prevalent in the aging western population.1 They are 
regarded as a major health problem associated with frequent hospitalization and 
increased mortality especially when occurring simultaneously. The development of 
cognitive impairment as a concomitant complication of cardiovascular disease has 
been an issue of growing interest in the past decades. With improvements in the 
prognosis of HF, improved survival after acute myocardial infarction, and an aging 
population, the burden of HF and its neuropsychological sequellae will continue to 
increase in the coming years.2
The effect of HF on cognitive performance is still a matter of debate. Reduced 
cardiac output may alter the oxygen and nutrient supply to the brain, thereby 
increasing the risk of cognitive deterioration.3 In addition, decreased cerebral 
perfusion leads to progressive cognitive dysfunction and may ultimately cause 
vascular dementia.4  Moreover, cerebrovascular pathologic changes, such as white 
matter lesions have been associated with cognitive impairment in patients with a 
variety of cardiovascular disease, including HF.5 In past decades, a number of 
studies focused on the underlying pathophysiological mechanisms in 
heterogeneous samples of patients with HF. These samples include heart 
transplant candidates and a variety of community-based populations.6
Methodological shortcomings in past studies include selection bias as well as the 
use of crude measures for cognitive function, such as the Mini Mental State 
Examination (MMSE). Moreover, previous studies using healthy controls or 
patients with other chronic diseases, on the whole, did not account for concomitant 
cardiovascular risk factors (e.g. hypertension and diabetes mellitus), also known to 
be associated with lower scores on cognitive tests.7;8
The objective of this study was to examine the profile of cognitive impairment in a 
representative sample of HF outpatients. HF patients were compared with healthy 
controls and with cardiac controls (i.e. patients with cardiac disease not 
complicated by HF) in order to disentangle the effects of general vascular disease 
from the specific effect of HF on cognitive functioning. We hypothesized that HF
patients show neuropsychological deficits resembling those seen in what is  
referred to as “vascular cognitive impairment”, predominantly consisting of impaired 
executive functions, decreased mental speed and attentional deficits.9
METHODS
Patients
We recruited 62 patients that had been attending a specialist HF outpatient clinic 
over a 12-month period. All subjects with a primary diagnosis of HF are referred to 
the outpatient clinic after discharge from the hospital. Participants had a
documented HF diagnosis with a minimum 6-month duration and had been stable 
on an optimized medication regimen for at least 1 month prior to entering the study. 
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Patients were considered eligible for participation in the study if they fulfilled the 
following criteria: (1) They were diagnosed with chronic HF in a stable state, 
functional class II-IV according to the New York Heart Association (NYHA) 
classification10; (2) they were aged 50 years or over;  (3) their left ventricular 
ejection fraction (LVEF) was lower than 40%.
Exclusion criteria were: psychiatric illness and other serious or life-threatening 
diseases (e.g. cancer), prior diagnosis of dementia, history of stroke associated 
with the development of neurological signs or symptoms, current diagnosis of 
depressive episode (ICD-10), use of psychoactive drugs, history of alcohol abuse 
(>4 units/day) and pacemaker-implants. Patients with pacemaker implants were 
excluded because our study is part of ongoing research which includes magnetic 
resonance imaging (MRI) of the brain. The reasons for exclusion during the 
screening procedures were pacemaker implants (53%), alcohol abuse (15%), 
stroke (15%), psychiatric illness (9%), dementia(2%), and “other” (6%). Twenty 
patients did not consent, mainly because of fatigue. 
In addition, we recruited 53 age-matched cardiac controls from the outpatient clinic 
of the cardiology department from the same hospital. All subjects had a history of 
ischemic cardiac disease but no clinical diagnosis of HF and a LVEF greater than 
40% on echocardiography. Our aim was to establish an equal distribution of 
cardiovascular risk factors in the cardiac control group. Finally, an age-matched 
comparison group of 42 healthy controls was studied, with no symptoms 
suggestive of HF or neurological disorders based on medical history and physical 
examination. Healthy control subjects were spouses or neurological outpatients, 
visiting the hospital for a peripheral nerve problem. The study was approved both 
by the institutional review board of the hospital and the national medical ethical 
committee. Informed consent was obtained from all subjects after the study’s 
procedures had been fully explained to them.
Clinical variables
Baseline data were collected in a structured interview including information on 
demographic characteristics, education and occupation, alcohol consumption, 
smoking habits, medical history, current use of medication and neurological 
complaints. Patients underwent physical examination, laboratory blood 
investigation and finally neuropsychological testing. In addition, serum 
apolipoprotein-E genotype (APOE), which is a risk factor for cognitive impairment 
and B-type natriuretic peptide (BNP), a biomarker for myocardial stress11, were 
determined. 
Diagnosis of Heart failure
The diagnosis of HF was determined by the clinical judgment of the attending 
cardiologist and categorized according to the NYHA classification. Clinical 
diagnosis of HF was consolidated by visualization of left ventricular dysfunction on 
bidimensional echocardiography, performed within an eight month period prior to 
screening. The LVEF was calculated by applying the modified Simpson’s rule.12
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Neuropsychological assessment
The assessments were performed by a trained clinical neuropsychologist, blinded 
to the patients’ diagnoses. The neuropsychological battery pertaining to five 
cognitive domains comprised the following tests: 
(I) Memory: 
(1) The Rey Auditory 15-word Verbal Learning Test (RAVLT): immediate 
and delayed verbal memory.13
(2) The Digit Span, part of the revised Wechsler Adult Intelligence Scale 
(WAIS-R): short-term memory.14
(3) Pattern Recognition Memory, part of the Cambridge 
Neuropsychological Test Automated Battery (CANTAB): recognition 
memory for patterns.15
(II) Executive functions: 
(1) Intra-Extra Dimensional Set Shift, part of the CANTAB: test of rule 
acquisition and reversal.15
(2) Stockings of Cambridge, part of the CANTAB: spatial planning test. 
(3) Trailmaking test-B: mental flexibility and concept shifting. 
(III) Visuospatial functions: 
(1) Fragmented line drawings in an ascending order of completeness: 
visuospatial perceptual abilities and object recognition. 
(2) The MMSE subscore for copying a visual figure: visuoconstructive 
abilities.16
(IV) Language: 
(1) Letter fluency and categorical fluency: controlled verbal production. 
(2) The MMSE component for language (naming, reading and writing).16
(V) Mental speed/attention: 
(1) The Stroop color-word test part 1 and 2: speed dependent mental 
flexibility. 
(2) Trailmaking test-A: attention/concentration and perceptual speed. 
The MMSE was administered to obtain an index of the overall cognitive 
performance according to Dutch norms.17 Premorbid intelligence level (IQ) was 
estimated using the Dutch version of the National Adult Reading Test.18 The 
affective status  (depression and anxiety) was assessed by the Symptoms Check 
List-90 (SCL-90).19 Neuropsychological data were missing for some patients who 
had not completed all 23 tests, consequently, sample size differs across the 
analysis. For one visuospatial task the instructions were missing in the initial 
neuropsychological protocol. Consequently, it was not administered to the first 
twenty patients, explaining the relative low sample size for this domain. 
Statistical analysis
Statistical analyses were performed using SPSS version 12.0.1 for Windows 
(SPSS, Inc., Chicago, Illinois). Group differences were evaluated using analyses of 
variance (ANOVA). Categorical data (gender, cardiovascular risk factors) were 
compared with chi-square tests. Z-scores were computed from the 
neuropsychological data and composite z-scores were defined for the five cognitive
domains, as described in the neuropsychological methods. The validity of this test 
classification was found to be satisfactory (Cronbachs α > 0.65). To indicate global 
cognitive performance a mean overall z-score was calculated that included the five 
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assessed domains. ANOVA’s with post hoc Bonferroni tests were used to asses 
group differences with respect to the neuropsychological data, correcting for age 
and gender. In a second model, depression and estimated IQ were additionally 
corrected for. MMSE scores, depression and anxiety scores were analyzed using 
the Kruskal-Wallis test for overall effect and the Mann-Whitney U test for analysis 
of the subgroups. In HF patients and cardiac controls we investigated potential 
disease related variables (duration of heart disease, depression, anxiety, estimated 
IQ, diastolic and systolic blood pressure, LVEF, NYHA-class, apoe-4 allele and 
BNP). These were entered into a multiple linear regression analysis to determine 
their independent relation to the overall cognitive z-score, controlling for age and 
gender. Significance was accepted at the level of p<0.05. 
RESULTS
Baseline characteristics are presented in table 1. Age and level of education were 
similarly distributed among the groups. The healthy control group contained more 
female participants, however, this difference did not prove significant. The 
estimated IQ scores in the cardiac control group were below those obtained for the 
HF patients and healthy controls.
Table 1. Baseline characteristics of heart failure patients, cardiac controls and healthy controls
Variables HF
(n=62)
Cardiac Controls 
(n=53)
Healthy Controls
(n=42)
p-value
Age 69.2 (9.2) 68.6 (9.5) 67.2 (9.2) 0.562
Education 4.5 (1.5) 4.3 (1.5) 4.9 (1.4) 0.179
Estimated IQ 99.5 (14.5) 92.8 (18.7) 103.8 (11.4) 0.001*
Gender female  16 (26%) 16 (30%) 19 (45%) 0.105
Diabetes Mellitus 16 (26%) 19 (36%) 0 0.243
Atrial Fibrillation 14 (23%) 6 (11%) 0 0.112
Hypercholesterolemia 28 (45%) 34 (64%) 0 0.047*
Hypertension 27 (44%) 24 (45%) 0 0.852
CABG 16 (26%) 20 (38%) 0 0.169
Occlusive artery disease 8 (13%) 11 (21%) 0 0.258
Presence Apo-E4 allele 16 (33%) 13 (25%) 12 (32%) 0.642
Smoking  23 (37%) 18 (34%) 5 (12%) 0.014†
LVEF 27 (7.3) 63 (8.2) - 0.000 
BNP 277.5 (405.6) 93.4 (145.5) 24.7 (19.9) 0.001
Systolic blood pressure 126.7 (16.8) 139.5 (19.6) 138.1 (18.4) 0.000
Diastolic blood pressure 77.3 (9.6) 80.9 (9.3) 82.9 (8.8) 0.008
Pulse 70.3 (10.7) 67.6 (10.9) 69.4 (11.9) 0.422
N antihypertensive drugs 2.79 (0.85) 2.06 (1.05) 0 0.000*
Duration of heart disease in 
years
5.0 (4.5) 7.6 (6.4) - 0.015*
Results are given as mean (standard deviation) except for numeric variables for which results are given 
as frequency (percentage). 
P-values for univariate analysis of variance F or χ² test.
* = P< 0.05 for comparisons between HF and cardiac controls. 
†= P< 0.05 for comparisons between HF and healthy controls.
CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; BNP, b-type natriuretic 
peptide.
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Etiology of cardiomyopathy in HF patients was determined as ischemic in 40 (65%) 
patients, dilated in 10 (16%), hypertrophic in 9 (15%) and as idiopathic in 3 (4%). 
Most HF patients were classified as NYHA class 2 or 3 with the duration of heart 
disease ranging from 1 to 15 years. There were no differences with respect to 
cardiovascular risk factors between the two patient groups, except for the 
significantly higher prevalence of hypercholesterolemia in the cardiac control 
group. Furthermore, significant baseline differences were found for LVEF, BNP, 
diastolic and systolic blood pressure, duration of heart disease and the number of 
antihypertensive drugs used. Consistent with their diagnosis of HF, these patients 
had lower blood pressure values, lower LVEF and higher BNP plasma levels. 
There were differences between groups in terms of the number of antihypertensive 
medications used. These medications included angiotensin-converting enzyme 
inhibitors, angiotensin receptor blockers, diuretics, beta blockers and calcium 
channel blockers.
Table 2. Neuropsychological test results of HF patients, cardiac controls and healthy controls
Neuropsychological test HF Cardiac 
Controls
Healthy 
Controls
p-value
RAVLT, immediate recall 37.8 (9.2) 40.6 (10.3) 41.8 (11.8) 0.127
RAVLT, delayed recall 7.2 (2.9) 8.8 (3.13) 8.1 (3.6) 0.032
Digit Span (WAIS-R) 12.4 (3.6) 11.9 (3.3) 13.8 (3.9) 0.043
Pattern Recognition Memory 20.6 (2.0) 21.0 (1.9) 21.6 (2.7) 0.072
Intra-Extra dimensional set 
shifting, number of errors
17.0 (10.7) 16.0 (10.5) 12.1 (9.8) 0.060
Stockings of Cambridge 7.15 (2.1) 7.78 (1.5) 8.34 (2.2) 0.015
Trail making test-A 55.8 (26.2) 48.3 (26.0) 44.0 (23.6) 0.115
Trail making test- B 151,8 (107.7) 151.5 (137.8) 115.7 (106.9) 0.255
Fragmented line drawings 10.5 (3.9) 11.9 (5.3) 13.9 (2.9) 0.009
Letter fluency
(Total score of 3 letters)
26.2 (12.5) 28.9 (10.8) 32.9 (11.7) 0.028
Categorical fluency
(Total score of 2 categories)
31.4 (8.7) 32.5 (9.5) 36.2 (8.9) 0.032
Stroop test part 1 53.8 (11.7) 51.1 (9.2) 47.0 (11.5) 0.008
Stroop test part 2 67.6 (13.4) 67.6 (14.8) 60.5 (11.6) 0.017
MMSE 27.6 (2.1) 27.6 (1.9) 28.1 (1.9) 0.387
Results are given as mean (standard deviation).
P-values for univariate analysis of variance F.
RAVLT, Rey Auditory 15-word Verbal Learning test; MMSE, Mini mental state examination.
The raw neuropsychological test results are presented in table 2. Table 3 
represents the composite domain scores and affective scores of the three groups. 
Results indicate a significant overall group effect on all assessed cognitive domains 
after correction for age and gender. Post hoc Bonferroni tests showed that HF
patients had significantly worse cognitive scores than healthy controls on all 
domains, whereas cardiac controls only differed from the healthy controls on the 
language domain. After additional correction for estimated IQ and depression, 
lower performance among HF patients remained significant on the domains of 
executive functions, language and mental speed as well as the overall cognitive 
function. Post hoc Bonferroni tests showed that HF patients performed worse than 
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cardiac controls in the domains of memory and mental speed.  The z-score for 
overall cognitive performance was significantly different for both subanalyses 
between groups, indicating worse general cognitive performance of HF patients, 
compared to cardiac and healthy controls. MMSE scores did not differ significantly 
between groups. Finally, symptoms of a depressed or anxious mood were similarly 
reported among the three groups. 
Table 3. Comparisons of the neuropsychological data of the study groups
Measures HF Cardiac 
Controls 
Healthy 
Controls
p1-value p2-value
Memory
N=142
-0.21 (0.59) -0.03 (0.66) 0.17 (0.89) P1 0.043† P2 0.023*
Executive functions
N=138
-0.19 (0.71) 0.01 (0.55) 0.28 (0.64) P1 0.003† P2 0.004†
Visuospatial functions
N=111
-0.20 (0.83) -0.09 (0.86) 0.26 (0.66) P1 0.019† P2 0.057
Language
N=148
-0.18 (0.74) -0.19 (0.79) 0.37 (0.69) P1 0.002†‡ P2 0.020†
Mental speed-attention
N=150
-0.19 (0.70) -0.01 (0.59) 0.22 (0.69) P1 0.033† P2 0.013*†
Overall cognitive 
function
N=104
-0.21 (0.57) 0.02 (0.45) 0.38 (0.43) P1 0.001†‡ P2 0.001*†
MMSE
N=151
27.6 (2.1) 27.6 (1.9) 28.1 (1.9) P1 0.243 P2 0.253
SCL-90 anxiety 14.7 (6.7) 14.1 (5.2) 13.3 (4.2) P1 0.379 -
SCL-90 depression 24.6 (10.1)  24.3 (8.9) 22.1 (6.2) P1 0.163 -
Results are given as mean z-score (standard deviation) except for MMSE, anxiety and depression
P1 = P-value for univariate analysis of variance F; data corrected for age and gender. 
P2 = P-value for univariate analysis of variance F; data corrected for age, gender, depression and 
estimated IQ.
*= P<0.05 for comparisons between HF and cardiac controls. 
†= P<0.05 for comparisons between HF and healthy controls.
‡= P<0.05 for comparisons between cardiac controls and healthy controls
HF, heart failure patients; MMSE, mini mental state examination; SCL-90, symptom check list-90.
An additional analysis using linear regression analysis (table 4) was performed to 
identify independent predictors of overall cognitive performance (dependent 
variable) in the two groups of patients. Estimated IQ, NYHA-class and presence of 
the APOE-e4 allele were independent predictors of worse cognitive performance in 
grouped HF patients and cardiac controls. 
To arrive at an indication for the prevalence of cognitive impairment in our sample 
we defined the mean overall cognitive z-score of the healthy participants minus 2 
standard deviations as the cut-off score for cognitive impairment. All patients 
performing below this cut-off z-score (-0.45) were regarded as being cognitively 
impaired. 11 of 44 (25%, p=0.042) HF patients were determined as cognitively 
impaired, as opposed to 5 of 34 (15%) in the cardiac control group and 1 of 26 
(4%) in the healthy control group. In contrast to the patients who were cognitively 
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intact, the impaired subjects were older, had lower systolic and diastolic blood 
pressure, longer duration of heart disease as well as lower estimated IQs. 
Symptoms of depression and anxiety were distributed equally among these groups.
Table 4. regression coefficients for parameters on overall cognitive score, corrected for Age and gender
Variables Coefficient β (SE)
Patient characteristics
Duration of heart disease
Depression
Anxiety
Estimated IQ
-0.076 (0.113)
 0.155 (1.579)
 0.035 (1.340)
 0.013 (0.003)*
Clinical and laboratory
BP diastolic
BP systolic
APOE-4-Allel
 0.075 (0.013)
 0.133 (0.042)
-0.370 (0.103)*
Cardiac parameters
LVEF
NYHA-class
BNP
 0.158 (0.025)
-0.237 (0.063)*
 0.031 (0.062)
*= p<0.01.
BP, blood pressure; APOE, apolipoprotein E; LVEF, left ventricular ejection fraction; NYHA, New York 
Heart Association; BNP, b-type natriuretic peptide.
DISCUSSION
We found that a significant proportion of HF patients display a pattern of cognitive 
impairment primarily including memory, mental speed and attention, language and 
global cognitive deficits. In contrast, the cardiac controls only performed worse than 
healthy controls in the domain of language and on the overall cognitive score. By 
including a cardiac control group, we were able to illustrate that HF patients were 
even more cognitively impaired than patients with a history of ischemic cardiac 
disease without evidence of HF, even though they had a comparable 
cardiovascular risk profile. In addition, the involvement of executive dysfunction as 
an important subset of cognitive functioning in HF patients is a relatively new 
finding. Neuropsychological tests that are designed to assess this important 
cognitive domain have been under-valued in earlier studies, underpinning the 
importance of this finding in our patient group. The Intra-Extra Dimensional Set 
Shift task is a test of visual discrimination and attentional set formation and 
flexibility. This test is primarily sensitive to changes to the fronto-striatal areas of 
the brain.20 Structural abnormalities of the frontal lobe and its connecting pathways 
may therefore be involved in the pathophysiological mechanism. 
This cognitive profile resembles that seen in “vascular cognitive impairment”, which 
includes prominent executive dysfunction.21 But in contrast to patients with vascular 
cognitive impairment, our findings in the HF group also revealed extensive memory 
deficits. Although HF patients are at risk for cerebrovascular damage, subcortical 
Chapter 3
52
ischemic vascular disease might therefore not be the sole explanation for the 
observed cognitive changes in HF patients.
The prevalence of cognitive deficits in our study conflicts with a number of 
published reports. Other authors22-25  found high prevalence rates for cognitive 
impairment ranging from 26-57% in patients with HF. These differences can 
probably be explained by the composition of our sample, consisting of outpatients 
in a clinically stable state of HF compared to older patients, hospitalized for HF in 
previous reports. Moreover, due to the range and specificity of our cognitive 
assessment battery, our results revealed even mild cognitive changes in practically 
all domains. These subtle, but nonetheless serious deficits may have been 
underestimated by other researchers.
Previous reports suggest a correlation between LVEF and cognitive decline.26;27 In 
our study, a lower LVEF showed a tendency toward a worse overall cognitive 
performance, however, this relation was not significant (p=0.068). Furthermore, we 
found that cognitive deficits became more prominent with increasing severity of 
illness, expressed by its independent relation to NYHA functional class. This 
association was independent of the duration of heart disease. In contrast to some 
previous reports25;28, in our study, the degree of cognitive dysfunction was not 
associated with systolic or diastolic blood pressure.
Another important finding is the relation of lower overall cognitive performance and 
the presence of ApoE-e4 allele in HF patients.  ApoE-e4 is an established risk 
factor associated with cognitive dysfunction and dementia.29 It is a protein involved 
in the modulation of cholesterol transport and homeostasis. Polymorphism of the 
ApoE gene has been implicated in many chronic cardiovascular and neuronal 
diseases. Recent studies indicate that the risk of substantial decline in cognitive 
function in the elderly may be modified by gene-environment interactions between 
ApoE genotype and cardiovascular risk factors.30;31 In our patient sample the 
presence of at least one ApoE-e4 allele was an independent predictor of cognitive 
impairment in multiple domains. To our knowledge, this finding has not been 
described previously in HF patients.
Pathophysiology
Cerebral hypoperfusion caused by reduced cardiac output as well as cardiogenic 
embolism have been proposed as the main underlying pathophysiological 
mechanisms causing cognitive deficits in HF patients.8 However, there is also a 
role for other vascular risk factors that are known to be related to cerebral white-
matter lesions and an increased risk of dementia.5 Data derived from the 
Rotterdam study indicate that these lesions are independently associated with a 
history of stroke or myocardial infarction, and they tend to be associated with lower 
scores on cognitive tests.32 Our study shows that the cardiovascular risk profile, 
which relates to white matter lesions (i.e. hypertension, atrial fibrillation and 
diabetes) was not significantly different among the HF patients and cardiac 
controls, therefore leaving HF as the major discriminator between groups as a 
probable cause of the observed cognitive deficits. We hypothesize that not the 
heart itself, but a common pathophysiological pathway that affects the 
microcirculation in both the heart and the brain could be responsible for the 
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observed mental deficits. HF patients, therefore, might in general be more 
susceptible than control subjects to vascular damage caused by cardiovascular risk 
factors such as hypertension, diabetes and genetic predisposition (e.g. Apo-E 
genotype).
Methodological limitations
Firstly, the recruitment of patients from the HF database could have introduced 
selection bias. A relatively high percentage of eligible subjects refused informed 
consent (n=20 (11%)), mainly because of fatigue. These patients may be in a more 
severe stage of heart disease, complicated by fatigue, or they felt depressed and 
were anxious about performing difficult mental tasks, revealing their deficits. The
prevalence of cognitive impairment might as a consequence be even higher in this 
patient sample. Fatigue, variable motivation and performance anxiety also occur in 
healthy controls but may especially in HF patients influence results, even after 
correction for depression. Second, testing was incomplete for some patients, 
excluding their data from the analysis, thus decreasing sample size and inducing 
bias. However, the baseline variables were not significantly different for patients 
with missing neuropsychological data and the missing data were equally distributed 
among the three groups. A remark has to be made about the letter and categorical 
fluency tasks. These are tests of controlled verbal production thought to not only 
involve language but also executive functions. Therefore, failure on the verbal 
fluency task may, at least partly, be the result of dysfunction in executive functions.
Clinical relevance
In contrast to most previous studies, our findings do not refer to end stage heart 
disease or hospitalized patients but to a varied group of outpatients with chronic 
HF, who are commonly seen in clinical practice. The cognitive deficits described in 
this paper, may explain the reported low compliance with therapy and complex 
rehabilitation programs.33
Because cognitive impairment may be subtle or even intermittent in the early 
stages of HF, routine screening is essential to ensure that it is detected and 
addressed adequately. 
Previous experience with effective HF-specific management programs has shown 
that a comprehensive individualized approach can significantly improve both 
duration and quality of life in HF patients. However, cognitively impaired patients 
fail to gain the same benefits in terms of prolonged event-free survival in relation to 
cognitively intact patients.34 Although reversibility of cognitive impairment after 
clinical treatment with medication, pacemaker implantation or heart transplantation 
is suggested by some authors35;36 it remains to be determined whether treatment 
can prevent cognitive deterioration from developing in early stages of heart 
disease. Investigation of disease modifying risk factors, like ApoE-e4, and 
cardiovascular predictors of neuropsychological decline that provide an opportunity 
for intervention, needs to be implemented in clinical practice. It may identify 
subjects at increased risk for developing cognitive impairment, and helps clinicians 
make informed decisions in developing an individual treatment regimen. 
Future studies should attempt to clarify the pathophysiological mechanisms that 
underlie cognitive impairment in HF and its dependence upon the interaction of 
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cardiological and non-cardiological factors which may precipitate the conversion of 
cognitive impairment to dementia. These factors include structural cerebral 
abnormalities that need adequate radiological and functional visualization of the 
brain.
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ABSTRACT
Background
Although heart failure (HF) is a common cardiovascular disorder, to date little 
research has been conducted into possible effects involving structural 
abnormalities of the brain. 
Aims
We purposed to determine the frequency and pattern of magnetic resonance 
imaging (MRI) abnormalities in outpatients with chronic HF, and to identify its 
demographic and clinical correlates. 
Methods
Brain MRI scans were compared between a sample of 58 HF patients, 48 controls 
diagnosed with cardiovascular disease uncomplicated by HF (cardiac controls) and 
42 healthy controls. Deep, periventricular and total white matter hyperintensities 
(WMH),  lacunar and cortical infarcts, global and medial temporal lobe atrophy 
(MTA) were investigated. We identified independent demographic and 
cardiovascular correlations of cerebral WMH and MTA. 
Results
Compared to cardiac and healthy controls, HF patients had significantly more 
WMH, lacunar infarcts and MTA whereas cardiac controls only had more MTA, 
compared to healthy controls. Age and left ventricular ejection fraction (LVEF) were 
independently associated with total WMH. Age and systolic hypotension were 
associated with MTA in HF patients and cardiac controls.
Conclusion
Our results suggest that cardiac dysfunction contributes independently to the 
development of cerebral MRI abnormalities in patients with HF. Age and low LVEF 
are the principal predictors of cerebral WMH in patients with HF and in cardiac 
controls.
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INTRODUCTION
Cerebral structural abnormalities, including white matter hyperintensities (WMH) 
are frequently detected on brain images of both asymptomatic and cognitively 
impaired elderly individuals. Many magnetic resonance imaging (MRI) based 
studies have demonstrated the existence of an association between WMH and risk 
factors for cerebrovascular disease.1-4 In addition, it has been suggested that the 
cardiovascular disease that leads to heart failure (HF) also involves a high risk of 
various cerebrovascular complications. To date only four studies have investigated 
structural brain abnormalities among HF patients.5-8 However, methodological 
shortcomings limit the interpretation of the results obtained. 
HF is a recognised risk factor for dementia and stroke.9-11 Cerebral hypoperfusion 
resulting from left ventricular dysfunction and cerebral emboli as a consequence of 
cardiac valvulopathies, arrhytmias and heart wall disorders have been held 
responsible for the observed cerebral changes.12 Among patients with HF and atrial 
fibrillation, the risk of cardiogenic stroke is two to four times greater for those 
between 50 and 80 years of age13 and, in case of multiple emboli may lead to 
vascular dementia.14
The cause of cerebral WMH, however, remains a matter of debate. They may be 
associated with ischemic cerebral changes resulting from various cerebrovascular 
risk factors1 or represent non-specific cerebral processes, such as normal aging 
and generalized vascular disease.15
In view of the increasing proportion of elderly individuals with HF in the population, 
the relative importance of the various risk factors for cerebral ischemic change 
must be determined as a matter of urgency. This is of particular importance in 
patients without clinical evidence of stroke or dementia, as risk factors might still be 
amenable to treatment or prevention.
The purpose of the present study was to prospectively determine the frequency 
and pattern of cerebral abnormalities in independently living outpatients with 
chronic HF, and to identify the demographic and clinical correlates involved. Aging 
and hypertension are important risk factors for cerebral WMH and global atrophy. 
We therefore used a case-control design, including HF patients, age-matched 
controls with a similar cardiovascular risk profile but without HF (cardiac controls), 
and healthy controls. Our working hypothesis was that both generalized 
cardiovascular burden and reduced cardiac function render HF patients more 
susceptible to cerebral damage, relative to cardiac controls and healthy controls. 
MATERIAL AND METHODS
Patients
The study population comprised consecutive patients with a primary diagnosis of 
HF, who were recruited from the cardiology outpatient department over a 12 month 
period. All of the participants had a documented diagnosis of HF, predating the 
study by at least six months. Furthermore, they had all been stable on an optimized 
medication regime for at least one month prior to the study. The diagnosis of HF 
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was based on the clinical judgement of the attending cardiologist and on two-
dimensional echocardiography. Left ventricular ejection fraction (LVEF) was 
calculated using the modified Simpson’s rule.16 Clinical status was categorized 
according to the New York Heart Association (NYHA) classification system.17
Patients were considered eligible to participate in the study if they fulfilled the 
following criteria: (1.) clinical diagnosis of chronic HF functional class II-IV 
according to the NYHA classification system; (2.) LVEF of less than 45%;  (3.) age 
50 or above; (4.) ability to undergo MRI scanning. Exclusion criteria were: 
psychiatric illness and other serious or life-threatening diseases, prior diagnosis of 
dementia, history of stroke associated with the development of neurological signs 
or symptoms, current diagnosis of depressive episode (ICD-10), use of 
psychoactive drugs, history of alcohol abuse (>4 units/day) or serious head injury 
and pacemaker-implant or other implanted metal devices. On the basis of the 
inclusion and exclusion criteria, 58 HF patients were found to be eligible for 
participation in the current study. 
In 65% of the HF patients, the aetiology of cardiomyopathy was determined to be 
ischemic. In 15% it was hypertrophic, in 4% it was idiopathic, while in 16% dilated 
cardiomyopathy was involved. This distribution of etiologic subgroups of HF, mainly 
involving ischemic cardiomyopathy, is thought to be representative of HF 
populations in general outpatient departments. Most HF patients were classified as 
NYHA class 2 or 3, with a history of heart disease ranging from 1 to 20 years. 
Medications used to treat hypertension included angiotensin-converting enzyme 
inhibitors, angiotensin receptor blockers, diuretics, beta blockers and calcium 
channel blockers. 
Cardiac control patients were simultaneously recruited from the Cardiology 
Outpatient Clinic. All 48 subjects had a history of ischemic cardiac disease but no 
clinical diagnosis of HF, in addition to a LVEF in excess of 45% (as measured by 
echocardiography). We aimed to establish an equal distribution of cardiovascular 
risk factors in the cardiac control group. Finally, an age-matched comparison group 
of 42 healthy controls was also studied. Healthy control subjects were spouses or 
neurological outpatients, visiting the hospital for a peripheral nerve problem. 
Neither their medical history nor a physical examination revealed symptoms 
suggestive of HF, central neurological disorders or cardiovascular risk factors. 
Baseline data were collected by means of a structured interview including 
information on demographic characteristics, smoking habits, relevant medical 
history, alcohol consumption, current use of medication, and neurological 
complaints. Historical and current clinical evidence of hypertension (blood pressure 
above 140 mm. systolic or 90 mm. diastolic), diabetes mellitus, coronary artery 
bypass graft (CABG), hypercholesterolemia or atrial fibrillation, were derived either 
from their medical files or from laboratory test results. The patients underwent a 
physical examination, laboratory blood tests, MRI brain scans, and 
neuropsychological testing. The laboratory blood tests included the b-type 
natriuretic peptide (BNP) that is regarded as a biomarker of myocardial stress.
The ethical review board approved the study. Written informed consent was 
obtained from all of the subjects, once the study’s procedures had been fully 
explained.
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MRI
Cerebral MRI was performed using a 1.5 tesla GE-Signa Horizon LX scanner. A 
standardized imaging protocol was used, consisting of sagittal T1-weighted 
(repetition time TR 300 ms, echo time TE 4 ms), axial T2-weighted (TR 6500 ms,
TE 105 ms) and fast fluid-attenuated inversion recovery (FLAIR) (TR 10000 ms, TE 
160 ms), as well as coronal flair images. A slice thickness of 5 mm with a 2mm
gap, was used for all images. 
WMH were rated using the Scheltens scale.18 Each cerebral region is initially 
scored on the size of the lesions, then on their number. In accordance with this 
scale, the periventricular white matter hyperintensities (PVH) were scored in three 
regions, the frontal and occipital caps, and the periventricular bands. They are 
rated as follows: none (score 0); 5 mm or less (score 1); confluent lesions and 
greater than 5 mm (score 2). The deep white matter hyperintensities (DWMH) were 
examined in four subcortical regions (frontal, parietal, temporal and occipital lobe). 
Five basal ganglia (BG) regions (caudate nucleus, putamen, globus pallidus, 
thalamus and internal capsule) were examined for hyperintensities and 
infratentorial foci of hyperintensities (ITF) were inspected in four regions 
(cerebellum, mesencephalon, pons and medulla). These lesions were rated as 
follows: none (score 0); 3 mm and less and five or less lesions (score 1); 3 mm or 
less and six or more lesions (score 2); 4–10 mm and five or less lesions (score 3); 
4–10 mm and six or more lesions (score 4); 10 mm or greater and one or more 
lesions (score 5); and large confluent lesions (score 6). The total white matter 
hyperintensities score (total WMH; range 0-30) represents the sum of the DWMH 
and PVH subscores. In addition, we used visual rating scales to evaluate MTA 
(possible range of scores for each side: 0 to 4)19, and global cortical atrophy 
(GCA)(possible range of scores: 0 to 3).20 Cortical and lacunar infarctions were 
recorded by number and location. The presence of DWMH, PVH and MTA is 
illustrated in figure 1.
Figure 1. Examples of abnormalities on neuroimaging
Deep white matter hyperintensities (1a), periventricular hyperintensities (1b), and medial temporal lobe 
artophy (1c) on axial (1a+b) and coronal (1c) fluid attenuated inversion recovery (FLAIR) sequences.
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Statistical analysis
Data analysis was performed by using SPSS version 12.0.1 for Windows (SPSS, 
Inc., Chicago, Ill). The total WMH score, DWMH, PVH, BG and ITF scores 
underwent square root transformation before statistical analysis to uphold a normal 
distribution. Group differences were evaluated by the use of analyses of variance 
(ANOVA). Categorical data (sex, cardiovascular risk factors) were compared using 
chi-square tests. ANOVAs with post hoc Bonferroni tests were used to assess 
group differences with respect to the MRI parameters, corrected for age and sex. A 
second model used age, sex, hypertension, smoking, diabetes and 
hypercholesterolemia as covariates. Where appropriate (MTA and global atrophy), 
data were analysed using nonparametric tests. In the two patient groups (HF and 
cardiac controls) partial correlations were calculated, controlling for age and sex in 
order to examine the association between baseline variables (cardiovascular 
parameters) and MRI variables. Variables (age, sex, LVEF, systolic blood 
pressure, NYHA-class, duration of heart disease, use of antihypertensive 
medication) which showed a significant correlation with MRI parameters were then 
entered into a stepwise multiple linear regression analysis, with total WMH and 
MTA as the dependent variables. The threshold of significance was set at 0.05.
RESULTS
Sample characteristics are presented in Table 1. 
Table 1. Baseline characteristics of heart failure patients (HF), cardiac controls and healthy controls
Variable HF
(n=58)
Cardiac 
Controls (n=48)
Healthy 
Controls (n=42)
p value
Age 68.7 (9.1) 68.9 (9.6) 67.2 (9.2) 0.629
Female sex 16 (26%) 16 (30%) 19 (45%) 0.105
Diabetes Mellitus 16 (26%) 19 (36%) 0 0.243
Atrial Fibrillation 14 (23%) 6 (11%) 0 0.112
Hypercholesterolemia 28 (45%) 34 (64%) 0 0.047*
Hypertension 27 (44%) 24 (45%) 0 0.852
CABG 16 (26%) 20 (38%) 0 0.169
Smoking 23 (37%) 18 (34%) 5 (12%) 0.014†‡
LVEF 27 (7.2) 63 (8.5) - 0.000*
BNP 282.1 (417.8) 97.0 (152.4) 24.7 (19.9) 0.002*†‡
Systolic blood pressure 125.5 (16.2) 140.7 (19.6) 138.1 (18.4) 0.000*†
Diastolic blood pressure 76.6 (9.1) 81.4 (9.4) 82.9 (8.8) 0.002*†
N antihypertensive drugs 2.79 (0.85) 2.06 (1.05) - 0.000*
Duration of heart disease in 
years
5.2 (4.5) 7.1 (6.2) - 0.000*
Results are given as mean (standard deviation) or frequency (percentage). 
P values for univariate analysis of variance F or χ² test.
*= p<0.05 for comparisons between HF and cardiac controls. 
†= p<0.05 for comparisons between HF and healthy controls.
‡ = p<0.05 for comparisons between cardiac controls and healthy controls.
HF, heart failure; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; BNP, b-
type natriuretic peptide.
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There were no differences between the patient groups with respect to age. The 
healthy control group contained relatively more female subjects than both patient 
groups, although the difference was not significant. With the exception of a higher 
prevalence of hypercholesterolemia in the cardiac control group, cardiovascular 
risk factors were equally distributed between the two patient groups. The groups 
differed significantly in terms of their smoking habits, with the lowest frequency 
reported among healthy controls. Furthermore, significant baseline differences 
were found for LVEF, BNP, systolic and diastolic blood pressure, number of 
antihypertensive drugs used, and duration of heart disease. Consistent with their 
diagnosis of HF, these patients presented with lower LVEF and higher BNP plasma 
levels. In addition, we found that HF patients had lower blood pressure values than 
either the cardiac controls or the healthy controls. Statins were used by 35 (66%) 
patients in the HF group and by 38 (79%) in the cardiac control group. Eleven of 
these patients had no prior documented diagnosis of hypercholesterolemia.
After correction for age and sex, the MRI findings shown in Table 2 indicate a 
group effect on total WMH, PVH, DWMH, BG, MTA and presence of lacunar 
infarcts. This group effect remained significant after additional correction for 
hypertension, diabetes, hypercholesterolemia and smoking. 
Table 2.  MRI findings in heart failure patients (HF), cardiac controls and healthy controls
MRI parameters HF
(n=58)
Cardiac 
Controls 
(n=48)
Healthy 
Controls
(n=42)
P1 value P2 value
Total WMH score 11.3 (7.3) 6.1 (4.2) 4.8 (3.9) <0.001 *,† <0.001 *,†
PVH 2.9 (1.7) 2.0 (1.1) 1.9 (1.1) 0.009 † 0.016 †
DWMH 8.3 (5.8) 4.0 (3.6) 2.9 (3.4) <0.001 *,† <0.001 *,†
BG 1.9 (2.9) 0.9 (1.8) 0.3 (0.7) 0.001 *,† 0.008 *,†
ITF 0.57 (1.4) 0.5 (1.2) 0.1 (0.5) 0.054 0.467
Global atrophy 1.1 (0.8) 0.9 (0.8) 0.7 (0.7) 0.139 0.088 
MTA 1.1 (0.9) 0.7 (0.7) 0.4 (0.6) <0.001 *,† <0.001 †,‡
Presence of lacunar 
infarcts
16 (28%) 7 (15%) 4 (10%) 0.009 † 0.017 *
Presence of cortical 
infarcts
8 (14%) 6 (13%) 1 (2%) 0.238 0.508
Results are given as mean (standard deviation) or frequency (percentage). 
P1 = p-value for univariate analysis of variance F or χ² test, corrected for age and sex 
P2 = p-value for univariate analysis of variance F or χ² test, corrected for age, sex, hypertension, 
diabetes, smoking and hypercholesterolemia.
* = p<0.05 for pairwise comparisons of mean difference between HF and cardiac controls. 
†= p<0.05 for pairwise comparisons of mean difference between HF and healthy controls.
‡= p<0.05 for pairwise comparisons of mean difference between cardiac controls and healthy controls
Corrected for age, sex, hypertension, smoking, diabetes and hypercholesterolemia.
WMH, white matter hyperintensities; PVH, periventricular hyperintensities; DWMH, deep white matter 
hyperintensities; BG, basal ganglia hyperintensities; ITF, infratentorial foci of hyperintensities; MTA, 
medial temporal lobe atrophy.
Post hoc analysis using Bonferroni correction showed that HF patients had a 
significantly greater number of abnormal MRI findings than either the cardiac 
controls or the healthy controls. The cardiac controls differed from the healthy 
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controls only in the degree of MTA. By contrast, the severity of GCA was similar in 
all three groups. In additional models in which we compared the MRI findings 
between the four different cardiomyopathy etiologic subgroups of HF patients no 
intergroup differences in severity of cerebral abnormalities were found (data not 
shown).
Partial correlation coefficients (adjusted for age and sex) of baseline cardiovascular 
variables with MRI parameters (Table 3) revealed associations with DWMH for 
systolic blood pressure, LVEF, NYHA class, duration of heart disease, and number 
of antihypertensive medications being used, whereas BG only correlated with 
LVEF. Significant correlations with PVH were found for LVEF and NYHA class.
Table 3. Results of analysis for partial correlations of baseline and clinical variables with MRI 
parameters, corrected for age and sex in the two patient groups
Variable Total 
WMH
PVH DWMH BG ITF Global
atro-
phy
MTA Lacu-
nar
infarcts
Systolic BP -0.182 -0.115 -0.202† -0.055 -0.156 0.006 -0.189† -0.034
Diastolic BP -0.064 0.066 -0.044 0.042 0.163 0.040 -0.124 0.101
LVEF -0.495* -0.290* -0.498* -0.249† -0.075 0.025 -0.200 -0.165
BNP 0.039 0.040 0.063 0.043 -0.021 0.000 0.022 -0.012
NYHA class 0.344* 0.313† 0.330* 0.188 -0.034 0.070 0.188 0.133
Duration of 
heart 
disease
0.320* 0.157 0.290* -0.027 0.019 0.149 0.250† 0.079
Number of 
medications
0.301* 0.130 0.274* 0.049 -0.079 0.098 0.247* 0.081
Data are Pearson correlation coefficients (r), uncorrected for multiple comparisons.
* = p<0.01
† = p<0.05
HF, heart failure; LVEF, left ventricular ejection fraction; BNP, b-type natriuretic peptide; NYHA, New 
York Heart Association; WMH, white matter hyperintensities; PVH, periventricular hyperintensities; 
DWMH, deep white matter hyperintensities; BG, basal ganglia hyperintensities; ITF, infratentorial foci of 
hyperintensities; MTA, medial temporal lobe atrophy.
Correlations with MTA involved systolic blood pressure, duration of heart disease 
and number of antihypertensive medications being used. 
A stepwise linear regression analysis was performed to identify any independent 
predictors of  WMH and MTA in the two patient groups. Age (β=0.043; SE=0.01; 
p<0.01) and LVEF (β=-0.029; SE=0.005; p<0.01) were independently associated 
with total WMH in both HF patients and cardiac controls (figure 2). Age (β=0.033; 
SE=0.005; p<0.01) and systolic blood pressure (β=-0.006; SE=.003; p=0.02) were 
associated with MTA. 
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Figure 2.  Relationship between the total WMH-score and the left ventricular ejection fraction (%)
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DISCUSSION
Our findings indicate that independently living HF outpatients, without clinical 
evidence of dementia or stroke display relatively frequent cerebral abnormalities, 
consisting of WMH, BG, lacunar infarcts and MTA. Using a case-control design, 
correcting for common cardiovascular risk factors we found that not the 
cardiovascular risk profile but the decreased heart function itself, represented by a 
low LVEF was independently related to the WMH in HF patients. The decreased 
cardiac function tended to affect the deep cerebral white matter more than it did the 
periventricular white matter. Furthermore, these cerebral WMH were found to be 
associated with the severity and duration of HF. The finding that systolic blood 
pressure was negatively related to DWMH can probably be explained by the 
antihypertensive treatment and low absolute blood pressure values in the HF 
group, compared to the cardiac controls. It may simply reflect the left ventricular 
dysfunction and antihypertensive treatment might further reduce cerebral perfusion 
in the presence of impaired cerebrovascular autoregulation.21
Only four studies have previously reported structural brain abnormalities in relation 
to cardiac function parameters among small numbers of patients with HF.5-8
Schmidt and colleagues found that patients who were suffering from idiopathic 
dilated cardiomyopathy exhibited a significantly higher rate of cerebral infarcts and 
cortical atrophy, and ventriculomegaly on MRI brain scan than twenty controls.6 In 
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contrast to our results, their MRI findings were not associated with LVEF or severity 
of illness. Two other studies found no significant differences between the 
prevalence of WMH in HF patients and in control subjects.5;7 Finally, Woo and 
colleagues reported the preliminary results of a study in which volumetric structural 
MRI scans were performed to assess regional gray matter volumes in nine patients 
with HF and in 27 healthy controls.8 The HF patients showed significant gray 
matter loss in deep cerebral structures and in areas related to autonomic and 
respiratory functions. However, small patient samples limit the interpretation of their 
results.
In HF patients, lower LVEF is the most important predictor of risk for cerebral 
infarction and ventricular thrombus formation.22 Not surprisingly therefore, our 
findings also indicated a high rate of silent cerebral infarction both in HF patients 
and in cardiac controls.
MTA, disproportional to global cerebral atrophy was another important finding in 
patients suffering from chronic HF. The high vulnerability of the temporal structures 
(i.e. hippocampus) to inadequate oxygenation that results from hypoperfusion may 
support a pathophysiological mechanism that is haemodynamically mediated, a 
view that is supported by this study’s finding that MTA was associated with the 
duration of HF. The recently reported association of HF with an increased risk of 
Alzheimer’s disease10 suggests that this finding is of considerable importance. To 
our knowledge no such finding has been reported previously.
The strength of our study lies in its use of a cardiac control group. This allowed us 
to adjust for common cardiovascular risk factors, thereby leaving HF as the major 
discriminator between patient groups. However, our study does have some 
methodological limitations, which need to be addressed. Firstly, we used visual 
rating scales while volumetric MRI analysis may be more accurate. Although widely 
used in the literature23, a MRI slice thickness of 5mm might furthermore have led to 
underdetection of small WMH. Nevertheless, recent studies have repeatedly 
reported similar results using either automated assessment methods or a visual 
rating scale.24;25 Secondly, the exclusion of patients with pacemaker devices might 
have introduced selection bias. These patients may be in a more severe state of 
HF, so their inclusion might have resulted in even more pronounced cerebral 
abnormalities in the HF group than was actually observed. 
Although the prevalence of hypertension was similar among the two patient groups, 
its premorbid severity and exact duration are difficult to measure. Substantial 
differences in lifetime exposure to such a cardinal risk factor for WMH like 
hypertension and the effects of treatment may therefore be masked in the two 
patient groups.
Pathophysiological considerations
Cardiovascular risk factors that frequently coexist in HF patients, such as 
hypertension, atrial fibrillation and hypercholesterolemia are regarded as the main 
cause of so-called “subcortical ischemic vascular disease” (SIVD).26 The lesions in 
SIVD arise from small vessel disease leading to incomplete white matter ischemia, 
lacunar strokes and areas of micro-infarction. In addition to micro-angiopathy, 
cerebral hypoperfusion due to left ventricular dysfunction may contribute equally to 
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the development of structural and functional cerebral abnormalities in HF patients. 
Recently, Roman discussed the susceptibility of elderly subjects to cerebral 
hypoperfusion as an important risk factor for the development of cognitive 
impairment and vascular dementia.14 He argued that both the white matter in the 
centrum semi-ovale and periventricular white matter, which are distal watershed 
territories irrigated by deep-penetrating medullary arteries, are particularly sensitive 
to hypoperfusion. Decreased auto-regulation, together with endothelial changes 
that result in blood-brain barrier dysfunction, lead to local hypoperfusion and 
incomplete infarction of the deep white matter. Moreover, it has been suggested 
that SIVD is associated with cortical and hippocampal atrophy.27 This relation has 
been linked to a deficient autoregulatory response and an increased risk of 
ischemic brain injury. Cerebral WMH may therefore provide a useful marker for 
more extensive cerebrovascular disease. Potentially, the cerebral perfusion deficits 
in this population may be further aggravated by the use of vasodilating agents. In 
the two patient groups of our study the number of antihypertensive medications 
used was positively correlated with the presence of total WMH and DWMH score. 
Nevertheless, these relations can be explained by collinearity with the duration and 
severity of heart disease.
In conclusion, our observations in HF patients, cardiac controls, and healthy 
controls support the notion that HF, in addition to general cardiovascular disease, 
imposes an increased risk of vascular brain abnormalities that are independently 
associated with left ventricular dysfunction. Next to WMH, MTA is an important 
element in this respect. It remains to be defined whether systematically MRI-
scanning of the brain can identify patients at risk of developing neurological and 
neuropsychological deficits in the early stages of heart disease.
Further studies are required to clarify the relation of structural brain abnormalities 
to the specific neuropsychological deficits encountered in these populations.
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ABSTRACT
Background/aims
We purposed to investigate the relationship between cerebral abnormalities 
detected by magnetic resonance imaging (MRI) and cognitive performance in 
nondemented outpatients with heart failure (HF).
Methods
In 58 patients with HF neuropsychological assessment was performed including 
tests of mental speed, executive functions, memory, language and visuospatial 
functions. Deep, periventricular and total white matter hyperintensities (WMH),  
lacunar and cortical infarcts, global and medial temporal lobe atrophy (MTA) were 
investigated on MRI of the brain. Correlations between MRI-findings and the 
cognitive measures were calculated. 
Results
MTA correlated with memory (r=-0.353, p<0.01), with executive functions (r=-
0.383, p<0.01) and the Mini Mental State Examination (r=-0.343, p<0.05). Total 
WMH and deep WMH were found to correlate with depression and anxiety scores, 
but not with cognitive measures. Age, estimated premorbid intelligence and MTA 
were independent predictors of diminished cognitive performance. 
Conclusions
In HF patients, MTA was related to cognitive dysfunction, involving memory 
impairment and executive dysfunction, whereas WMH was related to depression 
and anxiety.
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INTRODUCTION
Heart failure (HF) is an increasingly important and frequent complication of cardiac 
disease. With a reported incidence of 1-2%, it is one of the leading causes of 
hospitalization, morbidity and mortality in western countries.1;2 Due to the aging 
population in Western countries, the prevalence of HF is expected to reach 
epidemic proportions within the next 30 years.3
HF has been associated with cognitive impairment and dementia, particularly in the 
elderly. The neuropsychological deficits in these patients display a pattern of global 
cognitive impairment that primarily involves memory, attention and executive 
functions.4  Furthermore, depressive symptoms (an important confounding factor 
with regard to neuropsychological functioning) are extremely prevalent in patients 
affected by such chronic diseases as HF. 
Ischemic heart disease and hypertension are regarded as the main causes of HF. 
Together with diabetes mellitus and atrial fibrillation, they are also associated with 
cognitive dysfunction. In addition, coronary artery disease, atrial fibrillation, 
hypertension and diabetes have all been reported to be associated with lower 
scores on neuropsychological tests and with cerebrovascular disease, in particular 
cerebral infarcts and white matter hyperintensities.5;6 However, the contribution of 
these cerebral changes to cognitive impairment accompanying HF is probably 
complex and yet unknown. This is mainly a result of the paucity of studies into the 
relationship between these concomitant complications of generalized 
cardiovascular disease. Both cerebrovascular changes and general brain atrophy 
have been assumed to be responsible for the cognitive decline seen in HF 
patients.7 In general, previous studies in this area were handicapped by limited 
sample sizes and subject sampling bias, which tend to undermine the value of their 
results.7-9 Therefore, we performed a cross-sectional study in a well-defined group 
of nondemented outpatients with HF to investigate the relationship of cognitive 
performance to cerebral abnormalities on magnetic resonance imaging (MRI). 
Regarding the neuropsychological profile of cognitive impairment in HF, we 
hypothesized that not only vascular white matter changes and cerebral infarcts, but 
also atrophy of cerebral structures that related to memory, like the medial temporal 
lobe, would be involved in the underlying pathophysiology . 
METHODS
Patients
We recruited patients who attended a specialist HF outpatient clinic over a 12-
month period. All of these subjects had a documented diagnosis of HF of at least 6 
months duration.They were selected either from the HF patient database or 
consecutively on admission to the HF service. All of the participants had been 
stable on an optimized medication regime for at least one month prior to the study. 
The diagnosis of HF was based on the clinical judgment of the attending 
cardiologist and on two dimensional echocardiography. Left ventricular ejection 
fraction (LVEF) was calculated using the modified Simpson’s rule.10 Clinical status 
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was categorized according to the New York Heart Association (NYHA) 
classification.11
Patients were considered eligible to participate in the study if they fulfilled the 
following criteria: (1) a clinical diagnosis of chronic HF functional class II-IV 
according to the NYHA classification; (2) age 50 or above;  (3) a left ventricular 
ejection fraction (LVEF) lower than 45%; (4) ability to undergo MRI scanning.
The exclusion criteria were: psychiatric illness and other serious or life-threatening 
diseases, a prior diagnosis of dementia, a history of stroke associated with the 
development of neurological signs or symptoms, a current diagnosis of depressive 
episode (ICD-10), use of psychoactive drugs, a history of alcohol abuse (>4 
units/day) or serious head injury and a pacemaker-implant. 
On the basis of these inclusion and exclusion criteria, 62 HF patients were found to 
be eligible to participate in the current study. Fatigue and claustrophobia were the 
main reasons given by patients for not granting informed consent. Baseline data 
were collected by means of a structured interview, including information on 
demographic characteristics, smoking status, relevant medical history, level of 
alcohol consumption and current use of medication. Historical and current clinical 
evidence of hypertension (blood pressure above 140 mm. systolic or 90 mm. 
diastolic), diabetes mellitus, coronary artery bypass graft, hypercholesterolemia 
and atrial fibrillation were derived from the patients medical file or laboratory 
results. Patients underwent a physical examination, laboratory blood tests, MRI 
brain scans and a neuropsychological evaluation. The study was approved by the 
regional Medical Ethics Committee. Written informed consent was obtained from all 
of the subjects after the procedure had been fully explained to them.
Neuropsychological assessment
The neuropsychological assessment battery was administered by a trained 
neuropsychologist, unaware of the patient’s diagnosis. Where appropriate, subjects 
were given breaks to minimize the effects of fatigue on performance. The tests 
assessed five cognitive domains: 
(I) Memory (the Rey Auditory 15-word Verbal Learning Test12 and the Digit Span13
and pattern recognition memory, part of the Cambridge Neuropsychological Test 
Automated Battery (CANTAB)14); 
(II) Executive functions (Intra-extra dimensional set shift, part of the CANTAB14, 
Stockings Of Cambridge, also part of the CANTAB and the Trailmaking test-B15); 
(III) Visuospatial functions (fragmented line drawings and object recognition); 
(IV) Language (letter fluency and categorical fluency16); 
(V) Mental speed/attention (the Stroop color-word test part 2 and 317 and the 
Trailmaking test-A15). 
The Mini Mental State Examination (MMSE) was administered to obtain an index of 
the overall cognitive performance according to Dutch norms.18 Premorbid 
intelligence level (IQ) was estimated using the Dutch version of the National Adult 
Reading Test.19 Finally, the affective status (depression and anxiety) was assessed 
using the Symptoms Check List-90.20
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MRI
The MRI-brain scan was performed using a 1.5 Tesla scanner (GE-Signa Horizon 
LX). A standardized imaging protocol was used, consisting of sagittal T1-weighted 
(repetition time TR 300 ms, echo time TE 4 ms) and axial T2-weighted ( TR 6500 
ms, TE 105 ms) and fluid attenuated inversion recovery (FLAIR) weighted (TR 
10000 ms, TE 160 ms) as well as coronal FLAIR images. Scans were generated 
with a slice thickness of 5 mm with a 2 mm gap. MRI scans were read in a standard 
fashion by two experienced raters who were not provided with any clinical 
information. White matter hyperintensities (WMH) were rated according to the 
Scheltens scale.21 According to this scale the periventricular white matter 
hyperintensities (PVH) were being scored in three regions, frontal and occipital 
caps and periventricular bands. The deep white matter hyperintensities (DWMH) 
were examined according to size and number of lesions in four subcortical regions 
(frontal, parietal, temporal and occipital lobe), five basal ganglia regions (caudate 
nucleus, putamen, globus pallidus, thalamus and internal capsule) and four 
infratentorial regions (cerebellum, mesencephalon, pons and medulla). The total 
WMH (range 0-80) represented the sum of the DWMH and PVH subscores. In 
addition, we used visual rating scales to evaluate medial temporal lobe atrophy 
(MTA) (possible range of scores for each side: 0 to 4) 22, and global cortical atrophy 
(GCA; possible range of scores: 0 to 3)23. Cortical and lacunar infarcts were 
recorded by number and location. 
Statistical analysis
Data analysis was performed by using SPSS version 12.0 for Windows (SPSS, 
Inc., Chicago, Ill). Total WMH score, MTA, DWMH and PVH scores underwent 
square root transformation prior to statistical analysis to obtain a normal 
distribution. Z-scores were computed from the neuropsychological test results in 
order to standardize the data for analysis. Composite z-scores were defined for five 
cognitive domains, as described in the section on neuropsychological methods. To 
obtain an indication of overall cognitive performance a mean z-score was 
calculated that included the five domains assessed. The validity of this test 
classification was found to be satisfactory (Cronbachs α > 0.65).
Partial correlations were calculated, controlling for age, gender and estimated IQ in 
order to examine the association between MRI-findings (total WMH, PVH, DWMH) 
and neuropsychological outcomes. When appropriate (MTA and GCA), Spearman 
correlations were calculated.
Finally, we investigated a number of potentially disease-related variables (smoking, 
diabetes, hypertension, hypercholesterolemia, atrial fibrillation) and MRI-findings 
(PVH, DWMH, MTA and CGA). These were entered into a multiple stepwise linear 
regression analysis to determine their independent relationship to the overall 
cognitive z-score. The primary analyses were adjusted for age and gender (step 1, 
enter method) and in additional analyses also for estimated IQ and depression 
score. Significance was accepted at the level of p<0.05. 
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RESULTS
Four patients failed to complete the MRI protocol due to claustrophobia and were 
therefore excluded from the study. Imaging and neuropsychological data were 
obtained for 58 patients, whose clinical data are presented in table 1. The etiology 
of cardiomyopathy was found to be ischemic in 65% of the HF patients, dilated 
cardiomyopathy in 16%, hypertrophic in 15% and idiopathic in the remaining 4%. 
Thirty-seven patients were classified as NYHA class II, 18 as class III and 3 as 
class IV. The duration of heart disease ranged from 1 to 18 years. The medications 
used to treat hypertension included angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, diuretics, beta blockers and calcium channel 
blockers. LVEF ranged from 15% to 45%, with a mean of 27%. 
The mean total WMH score was 14 with a standard deviation (SD) of 9.5; mean 
scores for DWMH, PVH, MTA and GCA were 11 (SD 8.4), 3 (SD 1.7), 1 (SD 0.9) 
and 1 (SD 0.8). Twenty-eight percent of the patients had one or more lacunar 
infarcts and eight patients had a (clinically silent) cortical infarction. The mean 
MMSE score was 27.6, ranging from 24 to 30 points.
Partial correlation coefficients (adjusted for age, gender and estimated IQ) between 
the neuropsychological assessments and the MRI-findings are shown in table 2. 
Negative correlations were found between MTA and performance in the domains of 
memory and executive functions as well as overall cognitive domain score and the 
MMSE. Significant correlations with total WMH and DWMH were found for 
depression and anxiety scores, but not for any of the cognitive measures. Neither 
global cerebral atrophy nor PVH were related to any of the cognitive outcomes or 
measures of mood. 
Table 1. Baseline characteristics of heart failure patients
Variable Patients (n=58)
Age 68.7 (9.1)
Gender female 15 (26%)
LVEF 27 (7.2)
Systolic blood pressure 126 (16.2)
Diastolic blood pressure 77 (9.1)
Number of antihypertensive drugs 2.8 (0.9)
Duration of heart disease in years 5.2 (4.5)
Diabetes Mellitus 15 (26%)
Atrial Fibrillation 12 (21%)
Hypercholesterolemia 28 (48%)
Hypertension 25 (43%)
CABG 16 (28%)
Smoking 22 (38%)
MMSE-score 27.6 (0.28)
Results are given as mean (standard deviation) or frequency (percentage). 
CABG = history of coronary artery bypass graft; LVEF = left ventricular ejection fraction; BNP = b-type 
natriuretic peptide; MMSE = mini mental state examination.
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Stepwise linear regression analysis was performed to identify independent 
predictors (baseline covariates and MRI-findings) of overall cognitive performance. 
Age (β=-0.513; t=-4.473; p<0.01), estimated-IQ (β=0.401; t=3.88; p<0.01) and MTA 
(β=-0.392; t=-3.137; p<0.01) were independently associated with overall cognitive 
performance. 
In addition, we determined the prevalence of cognitive impairment in our sample by 
defining the mean overall cognitive z-score of 26 healthy subjects minus 2 standard 
deviations as the cut-off score for cognitive impairment. All patients performing 
below this cut-off z-score (-0.45) were regarded as being cognitively impaired. 14 
of 58 (24%, p=0.04) HF patients were determined as cognitively impaired, as 
opposed to 1 of 26 (4%) in the healthy control group.
Table 2. Partial correlation coefficients between neuropsychological outcomes and MRI findings
Neuropsychological 
measures
Total WMH DWMH PVH MTA GCA
Domain memory 0.092 0.105 -0.003 -0.353† -0.024
Executive functions -0.158 -0.128 -0.103 -0.383† -0.167
Domain language -0.175 0.102 0.088 -0.142 -0.075
Visuospatial functions  0.101 -0.226 0.111 -0.188 -0.124
Mental speed/attention -0.110 -0.099 -0.111 -0.115 -0.091
Overall cognitive score -0.090 -0.093 0.014 -0.383† -0.066
MMSE 0.193 0.196 0.095 -0.343* -0.099
SCL-90-R depression 0.314* 0.333* 0.162 0.024 -0.269
SCL-90-R anxiety 0.343* 0.342* 0.208 -0.049 -0.246
Data corrected for age, gender and estimated IQ.
*=p<.05
†=p<.01
WMH = white matter hyperintensities; PVH = periventricular hyperintensities; DWMH = deep white 
matter hyperintensities; MTA = medial temporal atrophy; GCA = global cortical atrophy; MMSE = Mini 
mental state examination; SCL-90 = symptom check list-90.
DISCUSSION
We found that MTA was associated with lower cognitive scores in nondemented 
patients with HF. Memory and executive functioning were the two most commonly 
affected domains associated with higher MTA-score. Linear regression analysis 
revealed that this association was independent of other MRI findings and 
cardiovascular risk factors (e.g. hypertension, diabetes mellitus).
Deep and total WMH were significantly associated with both depression and 
anxiety, whereas no relationship was found with the neuropsychological outcomes. 
The finding that MTA, but not WMH was related to cognitive performance in our 
population was remarkable. Nevertheless, these results are compatible with other 
reports in literature that were unable to demonstrate a consistent association 
between WMH and specific cognitive deficits in nondemented patients with 
cardiovascular disease.24;25 In independently functioning elderly without HF, other 
studies found that the presence of either severe WMH or MTA was associated with 
a modest but non-significant increase in frequency of mild cognitive deficits. 
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However, subjects with the combination of MTA and severe WMH had a more than 
fourfold increase in frequency of mild cognitive deficits.26
The high vulnerability of the medial temporal lobe to inadequate oxygenation 
resulting from hypoperfusion supports a hemodynamically mediated 
pathophysiological mechanism in patients with HF. In contrast to the clear 
association of abrupt interruptions in cardiac output to acute brain dysfunction, as 
seen in acute anoxic and hypoxic events, the cerebral effects of chronic reductions 
in cardiac output, as observed in HF patients, remain poorly understood. In HF, 
systolic dysfunction of the heart reduces the left ventricular ejection fraction and 
blood flow to the large cerebral arteries. Several authors8;27 reported regional blood 
flow reductions in severe HF patients as well as evidence for the failure of cerebral 
auto-regulation. Furthermore, recent evidence supports the hypothesis that, in 
addition to HF, chronic hypotension or excessive antihypertensive treatment also 
pose an increased risk of dementia.28;29
In patients with HF and multiple cardiovascular risk factors cognitive impairment is 
a frequent finding. Moreover, cerebrovascular pathology, in particular WMH, 
lacunar and cortical infarcts, is more common among these patients. Current 
epidemiological data show that vascular risk factors also predispose to Alzheimer’s 
disease.30 Despite the accumulation of evidence that interaction between the two 
types of pathology may be important in producing clinical signs of the disorder, 
questions remain in defining the mechanisms of this interaction. An obvious 
explanation for the relation between MTA and cognition that has been observed 
among patients with cerebrovascular disease is that these patients have 
concomitant Alzheimer’s disease.31 Considering the recently reported association 
of HF with an increased risk of Alzheimer’s disease29 the relation of MTA to the 
cognitive deficits seen in our sample may be an important finding.
Although the results clearly point towards a predominating role of MTA underlying 
cognitive impairment in HF the effects of WMH on cognitive performance may not 
yet be apparent in our sample of outpatients in a relative early stage of HF. The 
significant correlation between the presence of WMH and reported symptoms of 
anxiety and depression in HF patients is compatible with the results of previous 
studies32. It has been suggested that the emergence of depressive symptoms may 
be related to vascular damage to white matter tracts connecting cortical structures 
involved in the regulation of mood33. An indirect effect of depression on cognitive 
performance in our sample is unlikely, though. After adjustment for depression in 
the linear regression model the results on cognitive performance were essentially 
unchanged. An additional effect of WMH next to MTA on cognition can, however, 
not be excluded. In this respect the interaction between WMH and the occurrence 
of MTA that has been established in several previous reports, could well be of 
importance34. 
This is the first study to investigate neuroimaging and cardiovascular correlates in 
relation to cognitive performance in outpatients with HF. The strength of our study 
lies in the detailed neuropsychological and radiological investigation of a well-
defined sample of HF patients. Some methodological issues, however, need to be 
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addressed. The exclusion of patients with pacemaker devices and patients that 
refused informed consent on the grounds of fatigue may have led to some 
selection bias. These individuals may have been in a more advanced stage of 
heart disease. As a result, the prevalence of cerebral abnormalities and mental 
deficits may be even higher in these HF patients. Furthermore, we used visual 
rating scales while volumetric MRI analysis may be more accurate. However, 
previous reports have demonstrated good agreement between volumetric and 
visual rating scales35;36 and a more precise measurement of both WMH and MTA is 
expected to yield an even higher contrast than the crude visual method. Finally, the 
significance of the correlations could be a matter of debate, given the number of 
tests performed. 
Reversibility of cognitive impairment after medical treatment or heart 
transplantation has been suggested by some authors37;38. In view of our findings it 
could be suggested that this is more likely to occur in the early stages of heart 
disease before the brain has suffered structural damage. The investigation of 
structural brain abnormalities in HF could help identify patients who are at risk of 
developing cognitive deficits, while helping clinicians to develop an individual 
treatment regime.
References
1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-2018.
2. Murray-Thomas T, Cowie MR. Epidemiology and clinical aspects of congestive heart failure. J 
Renin Angiotensin Aldosterone Syst 2003;4:131-136.
3. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a 
heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure 
(REACH) study. J Am Coll Cardiol 2002;39:60-69.
4. Vogels RL, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive impairment in heart 
failure: A systematic review of the literature. Eur J Heart Fail 2007 May;9(5):440-9. 
5. de Groot JC, de Leeuw FE, Oudkerk M, Van Gijn J, Hofman A, Jolles J, Breteler MM. 
Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol 
2002;52:335-341.
6. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, Van Gijn J, Breteler MM. 
Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 
2002;125:765-772.
7. Schmidt R, Fazekas F, Offenbacher H, Dusleag J, Lechner H. Brain magnetic resonance 
imaging and neuropsychologic evaluation of patients with idiopathic dilated cardiomyopathy. 
Stroke 1991;22:195-199.
8. Alves TC, Rays J, Fraguas R, Jr., Wajngarten M, Meneghetti JC, Prando S, Busatto GF. 
Localized cerebral blood flow reductions in patients with heart failure: a study using 99mTc-
HMPAO SPECT. J Neuroimaging 2005;15:150-156.
Chapter 5
80
9. Woo MA, Macey PM, Fonarow GC, Hamilton MA, Harper RM. Regional brain gray matter loss in 
heart failure. J Appl Physiol 2003;95:677-684.
10. McGowan JH, Cleland JG. Reliability of reporting left ventricular systolic function by 
echocardiography: a systematic review of 3 methods. Am Heart J 2003;146:388-397.
11. Bennett JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA classes for 
measuring research outcomes in patients with cardiac disease. Heart Lung 2002;31:262-270.
12. Schoenberg MR, Dawson KA, Duff K, Patton D, Scott JG, Adams RL. Test performance and 
classification statistics for the Rey Auditory Verbal Learning Test in selected clinical samples. 
Arch Clin Neuropsychol 2006;
13. Wechsler D. Wechsler Adult Intelligence Scale-Revised (WAIS-R). San Antonio: The 
Psychological Corporation, 1981:
14. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge 
Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample 
of normal elderly volunteers. Dementia 1994;5:266-281.
15. Boll TJ, Reitan RM. Effect of age on performance of the Trail Making Test. Percept Mot Skills 
1973;36:691-694.
16. Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination, 3 ed. Iowa City: AJA 
Associates, 1983:
17. Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J. The Stroop color-word test: 
influence of age, sex, and education; and normative data for a large sample across the adult 
age range. Assessment 2006;13:62-79.
18. Kempen GI, Brilman EI, Ormel J. [The Mini Mental Status Examination. Normative data and a 
comparison of a 12-item and 20-item version in a sample survey of community-based elderly]. 
Tijdschr Gerontol Geriatr 1995;26:163-172.
19. Schmand B, Bakker D, Saan R, Louman J. [The Dutch Reading Test for Adults: a measure of 
premorbid intelligence level]. Tijdschr Gerontol Geriatr 1991;22:15-19.
20. Derogatis LR, Rickels K, Rock AF. The SCL-90 and the MMPI: a step in the validation of a new 
self-report scale. Br J Psychiatry 1976;128:280-289.
21. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, Steinling M, Valk J. A 
semiquantative rating scale for the assessment of signal hyperintensities on magnetic 
resonance imaging. J Neurol Sci 1993;114:7-12.
22. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, 
Wolters EC, Valk J. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease 
and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg 
Psychiatry 1992;55:967-972.
23. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and 
intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric 
infarcts. Eur Neurol 1996;36:268-272.
Neuroimaging and correlates of cognitive function among patients with heart failure
81
24. Mungas D, Jagust WJ, Reed BR, Kramer JH, Weiner MW, Schuff N, Norman D, Mack WJ, Willis 
L, Chui HC. MRI predictors of cognition in subcortical ischemic vascular disease and 
Alzheimer's disease. Neurology 2001;57:2229-2235.
25. O'Brien JT, Desmond P, Ames D, Schweitzer I, Tress B. Magnetic resonance imaging correlates 
of memory impairment in the healthy elderly: association with medial temporal lobe atrophy but 
not white matter lesions. Int J Geriatr Psychiatry 1997;12:369-374.
26. van der Flier WM, van Straaten EC, Barkhof F, Ferro JM, Pantoni L, Basile AM, Inzitari D, 
Erkinjuntti T, Wahlund LO, Rostrup E, Schmidt R, Fazekas F, Scheltens P. Medial temporal lobe 
atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-
disabled elderly people: the LADIS study. J Neurol Neurosurg Psychiatry 2005;76:1497-1500.
27. Georgiadis D, Sievert M, Cencetti S, Uhlmann F, Krivokuca M, Zierz S, Werdan K. 
Cerebrovascular reactivity is impaired in patients with cardiac failure. Eur Heart J 2000;21:407-
413.
28. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of 
dementia in very old individuals. Neurology 2003;61:1667-1672.
29. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of 
dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med 
2006;166:1003-1008.
30. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler 
Rep 2004;6:261-266.
31. Gorelick PB, Nyenhuis DL, Garron DC, Cochran E. Is vascular dementia really Alzheimer's 
disease or mixed dementia? Neuroepidemiology 1996;15:286-290.
32. Krishnan MS, O'Brien JT, Firbank MJ, Pantoni L, Carlucci G, Erkinjuntti T, Wallin A, Wahlund 
LO, Scheltens P, van Straaten EC, Inzitari D. Relationship between periventricular and deep 
white matter lesions and depressive symptoms in older people. The LADIS Study. Int J Geriatr 
Psychiatry 2006;21:983-989.
33. Kumar A, Thomas A, Lavretsky H, Yue K, Huda A, Curran J, Venkatraman T, Estanol L, Mintz J, 
Mega M, Toga A. Frontal white matter biochemical abnormalities in late-life major depression 
detected with proton magnetic resonance spectroscopy. Am J Psychiatry 2002;159:630-636.
34. de Leeuw FE, Barkhof F, Scheltens P. White matter lesions and hippocampal atrophy in 
Alzheimer's disease. Neurology 2004;62:310-312.
35. van Straaten EC, Fazekas F, Rostrup E, Scheltens P, Schmidt R, Pantoni L, Inzitari D, 
Waldemar G, Erkinjuntti T, Mantyla R, Wahlund LO, Barkhof F. Impact of white matter 
hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke 
2006;37:836-840.
36. Kapeller P, Barber R, Vermeulen RJ, Ader H, Scheltens P, Freidl W, Almkvist O, Moretti M, del 
Ser T, Vaghfeldt P, Enzinger C, Barkhof F, Inzitari D, Erkinjunti T, Schmidt R, Fazekas F. Visual 
rating of age-related white matter changes on magnetic resonance imaging: scale comparison, 
interrater agreement, and correlations with quantitative measurements. Stroke 2003;34:441-445.
37. Koide H, Kobayashi S, Kitani M, Tsunematsu T, Nakazawa Y. Improvement of cerebral blood 
flow and cognitive function following pacemaker implantation in patients with bradycardia. 
Gerontology 1994;40:279-285.
Chapter 5
82
38. Deshields TL, McDonough EM, Mannen RK, Miller LW. Psychological and cognitive status 
before and after heart transplantation. Gen Hosp Psychiatry 1996;18:62S-69S.
Chapter 6
Transcranial Doppler blood flow assessment in 
patients with heart failure: correlates with 
neuroimaging and cognitive performance
Congestive Heart Failure
In press
Raymond L.C. Vogels, MD1,4, Joukje M. Oosterman2, David M. Laman, MD, PhD3, Alida A. Gouw, MD4, 
Jutta M. Schroeder-Tanka, MD, PhD5, Philip Scheltens, MD, PhD4, Wiesje M. van der Flier, PhD4 and 
Henry C. Weinstein, MD, PhD1
1 Department of Neurology, Sint Lucas-Andreas Hospital, Amsterdam
2 Department of Clinical Neuropsychology, VU University, Amsterdam 
3 Department of Clinical Neurophysiology, Sint Lucas-Andreas Hospital, Amsterdam
4 Department of Neurology and Alzheimer Center, VU Medical Center, Amsterdam
5 Department of Cardiology, Sint Lucas-Andreas Hospital, Amsterdam, the Netherlands
Chapter 6
84
ABSTRACT
Background
Cardiac output and cerebral perfusion are reduced in patients with advanced 
stages of heart failure (HF). 
Aims
Our aim was to determine whether cerebral blood flow velocity (CBF-V), measured 
by transcranial Doppler ultrasound was reduced in outpatients with mild HF in 
comparison to controls, and if so, whether this reduction was related to cognitive 
performance and abnormalities of the brain diagnosed by magnetic resonance 
imaging (MRI).
Methods
CBF-V was determined in 46 outpatients with HF, 33 patients with cardiovascular 
disease but without evidence of HF and 22 healthy controls. Neuropsychological 
assessment consisted of an extensive test battery. White matter hyperintensities 
and medial temporal lobe atrophy were assessed by an MRI of the brain. 
Results and Conclusion
Mean middle cerebral artery CBF-V was lower in patients with mild to moderate 
HF, as compared to  healthy controls. No associations were found between the 
CBF-V parameters and the neuropsychological results or MRI abnormalities. 
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INTRODUCTION
Cognitive impairment is common among patients with chronic heart failure (HF).1 It 
is associated with both diminished health related quality of life2,3 and increased 
mortality.4 Reductions in cerebral blood flow as well as cardiogenic embolism have 
been held responsible for the observed cognitive deficits.5 Furthermore, 
hemodynamic changes in patients with HF and cardiovascular risk factors may 
contribute to morphologic cerebral abnormalities, in particular cerebral infarction 
and white matter hyperintensities (WMH).6,7 Recent studies indicate that brain 
perfusion is decreased and cerebral auto-regulation fails in advanced stages of 
HF.8 Transcranial Doppler (TCD) is an easy to administer and non-invasive tool for 
assessing cerebral blood flow velocity (CBF-V) reductions in patients with HF. Low 
CBF-V measured by TCD has already been described as a risk factor for WMH in 
the elderly.9 However, few data are available with regard to the relationship 
between decreased CBF-V and neuroimaging in outpatients with mild to moderate 
HF.10,11 Moreover, investigation of its possible relation to neuropsychological task 
performance may identify subjects at increased risk for developing cognitive 
impairment, and may provide an opportunity for intervention. 
Because of the high prevalence of a variety of vascular risk factors (e.g. 
hypertension and diabetes) and co-morbidity that may contribute to the 
development of cognitive decline in HF patients, the underlying pathophysiological 
mechanisms are difficult to identify and are as yet unknown. We therefore used a 
case-control design, including patients with cardiovascular disease but no evidence 
of HF (cardiac controls), to disentangle the specific effects of HF on the CBF-V. 
We hypothesized that HF was associated with decreased CBF-V, measured by 
TCD, compared to control subjects. Moreover, we expected that diminished CBF-V 
in HF patients was related to both neuropsychological deficits and cerebrovascular 
abnormalities, such as WMH.
METHODS
Patients
Fifty-two patients living independently were recruited from a specialist HF 
outpatient clinic over a 12-month period. Patients were considered eligible to 
participate in the study if they fulfilled the following criteria: (1) They were clinically 
diagnosed with chronic HF, functional class II-IV according to the New York Heart 
Association (NYHA) classification;12 (2) left ventricular ejection fraction (LVEF) was 
lower than 45% on transthoracic echocardiography; (3) they were aged 50 years or 
over. Criteria for exclusion were: psychiatric illness or use of psychoactive drugs, 
serious or life-threatening diseases, prior diagnosis of dementia, history of stroke 
associated with the development of neurological signs or symptoms, history of 
alcohol abuse (>4 units/day), myocardial infarction during the previous 3 months 
and pacemaker-implants. 
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In addition we recruited 36 cardiac controls from the outpatient clinic of the 
cardiology department. All of the participants had a history of ischemic cardiac 
disease without a clinical diagnosis of HF and a LVEF greater than 55%. We aimed 
to establish an equal distribution of cardiovascular risk factors in the two patient 
groups. Finally, a group of 25 healthy controls was studied. Healthy control 
subjects were healthy spouses or neurological outpatients, visiting the same 
hospital for a peripheral nerve problem. The study was approved by both the 
institutional review board of the hospital and the local research ethics committee.
Following informed consent, baseline data were collected by means of a structured 
interview including information on demographic characteristics, relevant medical 
history, alcohol consumption, current use of medication, and neurological 
complaints. Presence of hypertension, diabetes mellitus, coronary artery bypass 
graft, atrial fibrillation or hypercholesterolemia, was derived either from their 
medical files or from the laboratory test results. All participants underwent physical 
examination, laboratory blood tests, neuropsychological testing, and MRI brain 
scanning.
Transcranial Doppler
TCD was performed using a standard protocol with a 2-Mhz pulsed wave probe 
(Multidop X4 Doppler; DWL2.5 software). The study was performed with 
participants lying in a supine position without any visual or auditory stimulation. The 
middle cerebral artery (MCA) was insonated on both sides and data were obtained 
from measurements on three incrementing depths. The highest mean and systolic 
cerebral blood flow velocities (CBF-V) as well as the lowest pulsatility index (PI) 
were used in the analysis. TCD data were missing in 8 participants (4 in the HF 
group, 2 in the cardiac control group and 2 in the healthy control group) because of 
the bilateral absence of a temporal window. 
Hemodynamic significant stenosis of the internal carotid artery (ICA was estimated 
indirectly by means of asymmetric PI in both MCA using the pulsatility transmission 
index (lowest PI divided by the highest PI should be between 0.92 and 1.08).13
Another 2 patients in the HF group and 1 patient in the cardiac control group with a 
transmission index <0.92 were hereby excluded from the analysis.
MRI
MRI of the brain was performed using a 1.5 Tesla scanner (GE-Signa Horizon LX). 
A standardized imaging protocol consisting of sagittal T1-weighted (repetition time 
TR 300 ms, echo time TE 4 ms) and axial T2-weighted ( TR 6500 ms, TE 105 ms) 
and fluid attenuated inversion recovery (FLAIR) weighted (TR 10000 ms, TE 160 
ms) as well as coronal FLAIR images was used. Scans were generated with a slice 
thickness of 5 mm with a 2 mm gap. MRI scans were read in a standard fashion by 
two experienced raters who were not provided with any clinical information. WMH 
were rated according to the Scheltens scale.14 This scale scores the periventricular 
white matter hyperintensities (PVH) and deep white matter hyperintensities 
(DWMH) according to size and number of lesions in different regions. The total 
WMH (range 0-80) represented the sum of DWMH and PVH subscores. In 
addition, we used visual rating scales to evaluate medial temporal lobe atrophy 
(MTA) (possible range of scores for each side: 0 to 4).15
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Neuropsychological assessment
Five cognitive domains were assessed by an extensive neuropsychological battery: 
(I) Memory (the Rey Auditory 15-word Verbal Learning Test16 and the Digit Span17
and pattern recognition memory, part of the Cambridge Neuropsychological Test 
Automated Battery (CANTAB)18); (II) executive functions (Intra-extra dimensional 
set shift, part of the CANTAB,18 Stockings of Cambridge, also part of the CANTAB, 
and the Trailmaking test B19); (III) visuospatial functions (object recognition and
fragmented line drawings); (IV) language (letter fluency and categorical fluency20); 
(V) mental speed/attention (the Stroop color-word test part 2 and 321 and the 
Trailmaking test A19). In addition, the Mini Mental State Examination (MMSE) was 
administered.22 These tests were administered by a trained neuropsychologist, who 
was blinded to the subject’s group allocation. Neuropsychological data were 
missing for 3 patients who could not complete all tests. 
Statistical analysis 
Data were collated on Statistical Packages for the Social Sciences (SPSS), version 
12.0. Analyses of variance (ANOVA) were performed to assess intergroup 
differences in baseline data. Categorical data (gender, cardiovascular risk factors) 
were compared with chi-squared tests. Neuropsychological scores on the individual 
tests were transformed to Z-scores and composite Z-scores were defined for the 
five cognitive domains, as described in the neuropsychological methods. To obtain 
an indication of overall cognitive performance a mean Z-score was calculated. 
ANOVA’s with post hoc Bonferroni tests were used to asses group differences with 
respect to the TCD data, adjusting for age, gender and hematocrit.
The total WMH score and the MTA score underwent square root transformation 
before statistical analysis. In HF patients (n=46) a linear regression analysis was 
performed, controlling for age and gender, in order to examine the association
between TCD variables (dependent)  and both neuropsychological performance 
(composite cognitive Z-score and MMSE) and MRI parameters (WMH and MTA). 
RESULTS
TCD data were available for 79 patients and 22 healthy controls (table 1). The 
healthy control group was relatively younger and contained more female 
participants, although these differences did not reach statistical significance.
Cardiovascular risk factors were equally distributed among the two patient groups. 
Significant baseline differences were found for LVEF, BNP, diastolic and systolic 
blood pressure and smoking habits. HF patients had lower blood pressure values, 
lower LVEF and higher BNP plasma levels. There were differences between 
groups in terms of the number of antihypertensive medications used. These 
medications included angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers, diuretics, beta blockers and calcium channel blockers. Aetiology 
of cardiomyopathy in HF patients was ischemic in 30 (65%) patients, dilated in 9 
(20%), hypertrophic in 5 (11%) and idiopathic in 2 (4%). Twenty-two HF patients 
were classified as NYHA class II, twenty-one as class III and three as class IV, with 
duration of heart disease ranging from 1 to 12 years. 
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Table 1. Baseline characteristics of heart failure patients, cardiac controls and healthy controls
Variables HF
(n=46)
Cardiac Controls
(n=33)
Healthy Controls
(n=22)
p-value
Age 68.1 (8.9) 67.8 (9.7) 64.1 (8.3) 0.093
Gender female   9 (20%)  6 (21%)  10 (45%) 0.082
Diabetes Mellitus 11 (23%) 7 (22%) 0 0.941
Atrial Fibrillation 7 (15%) 4 (11%) 0 0.387
Hypercholesterolemia 21 (46%) 21 (64%) 0 0.103
Hypertension 21 (46%) 16 (47%) 0 0.901
CABG 13 (29%) 12 (36%) 0 0.506
Occlusive artery disease 7 (15%) 7 (22%) 0 0.372
Smoking  18 (40%) 15 (44%) 4 (18%) 0.015†
LVEF 27 (7.3) 63 (8.2) - 0.000*
BNP 277.5 (405.6) 93.4 (145.5) 24.7 (19.9) 0.001*†
Systolic blood pressure 125.4 (15.5) 140.2 (15.4) 133.4 (16.4) 0.000*
Diastolic blood pressure 76.5 (9.5) 83.3 (7.7) 83.2 (9.3) 0.001*†
Pulse 69.3 (10.7) 67.6 (10.7) 68.2 (12.4) 0.798
Hematocrit 0.40 (0.04) 0.41 (0.03) 0.40 (0.03) 0.128
Results are given as mean (standard deviation) except for numeric variables for which results are given 
as frequency (percentage). 
P-values for univariate analysis of variance F or χ² test.
* = P< 0.05 for comparisons between HF and cardiac controls. 
†= P< 0.05 for comparisons between HF and healthy controls.
LVEF, left ventricular ejection fraction; BNP, b-type natriuretic peptide; MMSE, Mini Mental State 
Examination.
Table 2 represents the composite domain scores of the three groups, adjusted for 
age, gender and education. Results indicate a significant overall group effect on 
the cognitive domains memory, executive functions, mental speed/attention and 
the overall cognitive z-score. Mean MMSE scores were similar in the three groups.
Table 2. Neuropsychological data in the three study-groups
.
Neuropsychological 
domain
HF
(n=46)
Cardiac Controls
(n=33)
Healthy Controls
(n=22)
p-value
Memory -0.23 (0.61) 0.10 (0.53) 0.27 (0.93) 0.014
Executive functions -0.17 (0.66) 0.05 (0.54) 0.33 (0.64) 0.027
Language -0.13 (0.80) -0.04 (0.77) 0.35 (0.71) 0.214
Visuospatial functions -0.10 (0.58) 0.15 (0.37) 0.25 (0.70) 0.051
Mental speed/attention -0.13 (0.59) 0.08 (0.52) 0.24 (0.75) 0.044
Overall cognitive score -0.15 (0.45) 0.05 (0.38) 0.29 (0.60) 0.003
MMSE 27.6 (2.1) 27.5 (1.97) 28.1  (1.91) 0.361
Results are given as mean (standard deviation); P-value for univariate analysis of variance F; data 
corrected for age, gender and education.
Mean MCA CBF-V differed significantly between HF patients and healthy controls, 
but not between the HF patients and the cardiac controls (table 3). The MCA PI 
was significantly higher in the two patient groups relative to the healthy control 
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group. After additional correction for age, gender and hematocrit this group effect 
remained significant for HF patients and healthy controls. 
Table 3. Comparisons of transcranial Doppler data of the study groups
Transcranial 
Doppler Variables
HF Cardiac 
Controls
Healthy 
Controls
p1-value p2-value
Mean MCA CBF-V  
cm/sec.
47.1 (12.1) 49.8 (11.2) 56.1 (10.9) P1 0.011† P2 0.035†
Systolic MCA CBF-V 
cm/sec.
80.4 (18.0) 82.7 (19.2) 86.1 (15.5) P1 0.473 P2 0.601
MCA Pulsatility index 
cm/sec.
0.94 (0.21) 0.95 (0.16) 0.79 (0.13) P1 0.003†‡ P2 0.046†
Results are given as mean values (standard deviation).
P1 = P-value for univariate analysis of variance F; uncorrected data. 
P2 = P-value for univariate analysis of variance F; data corrected for age, gender and hematocrit.
*= P<0.05 for comparisons between HF and cardiac controls. 
†= P<0.05 for comparisons between HF and healthy controls.
‡= P<0.05 for comparisons between cardiac controls and healthy controls.
HF, heart failure patients; MCA, middle cerebral artery; CBF-V, cerebral blood flow velocity.
Linear regression analyses in the sample of HF patients showed that CBF-V 
variables were not correlated to any of the MRI measures or the total cognitive 
domain Z-score and MMSE (table 4.). Neither were the CBF-V parameters 
correlated to the LVEF or systolic and diastolic blood pressure. 
Table 4. Linear regression coefficients of CBF-V parameters on MRI measures and cognitive 
performance in heart failure patients
Mean CBF-V Systolic CBF-V Pulsatility index
Dependent variables β SE β SE β SE
Total WMH -0.002 0.018 -0.004 0.11 -0.070 0.911
MTA 0.002 0.007 -0.001 0.004 -0.223 0.353
Total cognitive Z-score -0.030 0.018 -0.014 0.010 -0.864 0.917
MMSE -0.001 0.007 0.001 0.004 0.422 0.375
Results given as Beta-coefficients (β) and standardized error (SE). Results were not significant.
CBF-V, cerebral blood flow velocity; MTA, medial temporal lobe atrophy; WMH, white matter 
hyperintensities.
DISCUSSION
We found that patients with mild to moderate HF had a lower mean CBF-V of the 
middle cerebral artery compared to healthy subjects. In contrast to what we 
expected, this CBF-V reduction was not related to cognitive performance or brain 
abnormalities as observed on MRI. 
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The CBF-V measured by TCD is an indirect estimate of actual cerebral perfusion. 
Equivalence between both variables, has been suggested by some studies, but 
challenged by others.23,24 It can be assumed, however, that in a large sample of 
subjects with TCD examinations performed under the same conditions, CBF-V is a 
good surrogate of cerebral blood flow and that the observed group differences 
actually reflect differences in cerebral blood flow.
Cross-sectional studies have shown that patients with HF have a decreased 
cerebral blood flow and impaired cerebral autoregulation.8,10,25,26 The present 
series is distinct from the previous studies in that it includes outpatients with HF 
living independently and a cardiac control group with a comparable cardiovascular 
risk profile but no evidence of HF. These cardiac controls also showed a reduction 
in CBF-V compared to healthy controls, however, this difference did not reach 
statistical significance. CBF-V reductions in HF can therefore not be exclusively 
attributed to systolic dysfunction of the heart leading to low cardiac output. 
Cardiovascular risk factors, that were highly prevalent in the two patients groups, 
may also play a role. 
In contrast to patients with advanced stages of HF, our sample of outpatients had 
relatively mild cerebral blood flow reductions. In the early stages of heart disease 
the effect of left ventricular dysfunction may still be compensated by cerebral 
autoregulatory mechanisms that are intact, and as a consequence may not lead to 
permanent cerebral hypoperfusion that can be detected by TCD. This may be an 
explanation for the fact that we were unable to demonstrate a correlation between 
the changes in CBF-V parameters and the cognitive performance or neuroimaging 
abnormalities. This finding contrasts with the few studies on this topic that have 
yielded conflicting results: one suggested that both low mean CBF-V of the middle 
cerebral artery and high pulsatility index were correlated with the MMSE score.10
The median MMSE score of the population in that study was 23 and patients were 
younger in age (mean 55) than our patients. Alves and colleagues used a voxel-
based image analysis method to investigate the presence of regional cerebral
blood flow abnormalities in HF patients compared to healthy controls.27 They found 
a direct relationship between cerebral blood flow and degree of cognitive 
impairment. Others have shown low mean CBF-V in HF patients that improved 
after cardiac transplantation, but unfortunately no cognitive data were reported.11,28
In these studies, sample size was limited and selection bias was likely because of 
the complex methods used (single photon emission computed tomography or 
positron emission tomography scanning).
The existence of cerebrovascular autoregulatory mechanisms, ensuring cerebral 
perfusion when systemic blood pressure falls, gave rise to the hypothesis of a non-
linear relation between low CBF-V values and MRI brain abnormalities. Therefore, 
we performed an additional analysis in which we found that only a small sample of 
nine HF patients with a systolic CBF-V below a cut-off value of 62.5 cm/sec had a 
higher total WMH score compared to the thirty-seven patients with higher systolic 
CBF-V values. This finding is an association of which the direction remains 
speculative. A plausible explanation is that microangiopathy caused by multiple 
cardiovascular risk factors like hypertension and diabetes mellitus causes a 
decrease in CBF-V and cerebral perfusion, which would contribute to the 
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occurrence of WMH. Another explanation considered is that, in addition to 
microangiopathy, cerebral hypoperfusion due to left ventricular systolic dysfunction 
leads to incomplete white matter ischemia, lacunar strokes and areas of micro-
infarction. However, our results have shown that the observed reductions in CBF-V 
did not relate to the LVEF. As a consequence, one may hypothesize that 
assessment of the CBF-V in the large cerebral arteries does not reflect the capillary 
perfusion in the deep white matter that is thought to be affected by chronic 
hypoperfusion. Apart from pathophysiological considerations our study has shown 
that although patients with mild to moderate HF have a lower CBF-V compared to 
healthy subjects, this reduction was not yet related to cognitive performance or 
neuroimaging abnormalities in this stage of heart disease.
Some methodological limitations of our study need to be addressed. The relatively 
small number of patients inevitably leads to limitation of the statistical power of the 
data. Secondly, the recruitment of patients from a specialist HF service may have 
led to selection bias, as 18% of the screened patients refused informed consent, 
because of fatigue or claustrophobia. Nevertheless, we believe that our sample is 
representative of an outpatient HF population. Thirdly, the study was essentially 
correlational, which limits interpretations about causal mechanisms underlying 
cognitive impairment associated with brain perfusion. Finally, we intended to 
exclude patients with a hemodynamically significant ICA stenosis by using the 
pulsatility transmission index but no actual duplex of the carotids was performed. 
We believe however, that this index is a reliable estimate of actual severe ICA 
stenosis.13
Patients with mild to moderate HF have a lower mean CBF-V of the middle 
cerebral artery measured by TCD compared to healthy subjects. In the investigated 
population, these reductions were not associated with WMH, MTA or with cognitive 
performance. Longitudinal studies are needed to help further elucidate the relation 
between cerebral hemodynamic disturbances in patients with refractory HF and 
cognitive impairment.
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SUMMARY AND GENERAL DISCUSSION 
In this chapter, the main findings and conclusions of the studies presented in this 
thesis are summarized and discussed. Attention is given to general methodological 
issues and the clinical relevance of our findings. In addition, the implications for 
further clinical practice are described. Finally, we give some recommendations for 
future research.
SUMMARY
The issues discussed in this thesis result from a systematic literature review 
addressing the association between heart failure (HF) and cognitive impairment. 
This review and meta-analysis are being described in chapter 2. Pooled analysis of 
data derived from 22 reviewed studies showed diminished neuropsychological 
performance expressed by significant differences in effect sizes for memory scores 
and psychomotor speed/attention when comparing HF patients with controls. In a 
pooled sample of 2937 heart-failure patients and 14848 control subjects, the odds 
ratio for cognitive impairment was 1.62 (95% confidence interval:1.48-1.79, 
p<0.0001) among subjects with HF. Review of the literature also showed that 
depression was more prevalent among patients with HF. Although 
neuropsychological data are becoming increasingly available in these populations, 
our review made clear that many of these studies had major methodological 
limitations. Particularly, the lack of studies that systematically performed 
neuropsychological examinations by use of an extensive battery was striking. 
Information on the prevalence and severity of cognitive impairment in the different 
etiological subgroups of HF was therefore not interpretable. With respect to 
underlying pathophysiological mechanisms, assessment of alterations in brain 
structures by neuroimaging was sparse or unrepresentative of general populations 
with HF.
In chapter three, a sample of 64 HF outpatients, 53 controls diagnosed with 
cardiovascular disease uncomplicated by HF (cardiac controls) and 42 healthy 
controls underwent neuropsychological assessment including tests of mental 
speed, executive functions, memory, language and visuospatial functions, as well 
as measures of cardiovascular function and laboratory investigation. Effect sizes 
(z-scores) were computed from the neuropsychological data and composite z-
scores were defined for five cognitive domains. Global cognitive performance was 
estimated by calculating a mean overall z-score that included these five assessed 
domains. Neuropsychological performance was compared between the three 
groups. Independent demographic and clinical predictors of cognitive impairment 
were identified with linear regression analysis, thereby adjusting for confounding 
cardiovascular risk factors. The findings showed that HF patients demonstrated a 
pattern of general cognitive impairment, that included executive functions, memory, 
mental speed and attention. Cognitive impairment was present in 25% of HF 
patients, relative to 15% of the cardiac controls and 4% of the healthy controls. 
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Age, estimated intelligence, NYHA-class and presence of the apolipoprotein E-4 
allele were independent determinants of cognitive impairment in HF patients.
Chapter 4 describes the results of neuroimaging in a sample of 58 HF patients, 48 
cardiac controls and 42 healthy controls. Presence and severity of deep, 
periventricular and total white matter hyperintensities (WMH),  lacunar and cortical 
infarcts, global and medial temporal lobe atrophy (MTA) were compared between 
groups. The results of the brain magnetic resonance imaging (MRI) showed that 
HF patients had significantly more WMH, lacunar infarcts and MTA, whereas 
cardiac controls only had more MTA, compared to healthy controls. Age and left 
ventricular ejection fraction (LVEF) were independently associated with total WMH. 
Age and systolic hypotension were associated with MTA in HF patients and cardiac 
controls.
The possible relationship between the main findings described in chapter 3 and 4 
is further evaluated in chapter 5. Here we investigated the relationship of cognitive 
performance to cerebral abnormalities on magnetic resonance imaging (MRI) in 58 
nondemented outpatients with HF. Correlations between MRI-parameters and the 
cognitive measures were calculated and independent baseline correlates of overall 
cognitive performance were identified with stepwise linear regression analysis. The 
results of this study indicated that MTA correlated with memory (r=-0.353, p<0.01) 
and executive functions (r=-0.383, p<0.01) as well as the overall cognitive domain 
score (r=-0.383, p<0.01) and the Mini Mental State Examination(r=-0.343, p<0.05). 
Total WMH and deep WMH were found to correlate with depression and anxiety 
scores, but not with cognitive measures. Not surprisingly, age and estimated 
premorbid intelligence but, more important, MTA were independent predictors of 
worse cognitive performance in HF patients.
Chapter 6 addressed the hypothesis that cerebral hypoperfusion is one of the main 
mechanisms underlying cognitive impairment in HF. To investigate the relation of 
cerebral blood flow reductions to the cognitive deficits and MRI brain abnormalities, 
described in the previous chapters, we determined the cerebral blood flow velocity 
(CBF-V), measured by transcranial doppler ultrasound (TCD) in 46 outpatients with 
HF, 33 cardiac controls and 22 healthy controls. The findings of this study 
confirmed the hypothesis that CBF-V was reduced in outpatients with HF 
compared to controls. The mean middle cerebral artery (ACM) CBF-V differed 
significantly between HF patients (47.1 cm/sec) and healthy controls (56.1 cm/sec), 
but not between the HF patients and the cardiac controls (49.8 cm/sec). The ACM 
pulsatility index was significantly higher in the two patient groups relative to the 
healthy controls. Against our expectation, no correlations were found between the 
neuropsychological results and the CBF-V parameters. But, in concordance with 
other reports in literature, deep and total WMH were more prevalent in HF patients 
with a systolic CBF-V of less than 62.5 cm/sec.
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GENERAL DISCUSSION
With improvements in the prognosis of HF and improved survival after acute 
myocardial infarction in the aging population, the burden of HF and it’s 
neuropsychological sequellae are expected to increase in the coming years.1
Cognitive impairment in turn has proven to be a powerful, independent predictor of 
mortality and decreased quality of life in these patients. Similarly to previous 
reports, our study provides evidence that the relationship between cognitive deficits 
and chronic HF is independent of socio-demographic variables. Moreover, we were 
able to demonstrate that this relationship was independent of common 
cardiovascular risk factors such as hypertension and diabetes mellitus. The 
inclusion of a cardiac control group allowed us to adjust for these risk factors, 
thereby leaving HF as the major discriminator between patient groups. 
Profile of cognitive impairment
By using an extensive neuropsychological test battery we could illustrate that the 
pattern of cognitive impairment primarily included memory, executive functions, 
mental speed and attention, language and global cognitive deficits. In most other 
studies a single measure was considered sufficient to detect problems in cognition. 
Had we used only the MMSE and the cut-off-point score used by others (<24) , 
only 2% of the HF sample would have been suspected of being cognitively 
impaired. The difference between the percentage thought to be cognitively 
impaired in our study and the percentages in other studies that used the MMSE or 
comparable tests may be due to our outpatient sample with relative mild symptoms 
of HF and the difference in educational level. Particularly in the early stages of 
heart disease cognitive impairment may be intermittent or subtle and thus not 
easily recognized. The most important shortcoming of previous studies, however, is 
that most screenings tests, such as the MMSE, are not sensitive enough to detect 
mild cognitive impairment in HF patients as they were designed to identify cognitive 
symptoms, as in Alzheimer’s disease (AD). 
The cognitive profile of HF patients described in chapter 2 of this thesis resembles 
that seen in so called “vascular cognitive impairment”(VCI), which includes 
prominent executive dysfunction.2 But some important remarks have to be made 
on the relevance of this finding that form the basis of this thesis. VCI covers a wide 
spectrum of cognitive impairment ranging from subtle deficits to overt dementia. 
The concept of VCI is thought to be associated with the presence of subcortical 
ischemic vascular disease (SIVD), defined by specific features on MRI.3 It arises 
from small vessel disease and is characterised by extensive WMH and lacunar 
infarcts in deep cerebral gray as well as white matter structures. It has been 
suggested that the neuropsychological features in patients with SIVD can be 
distinguished from other forms of dementia, such as AD, by a better recognition 
memory, but worse executive function. Particularly the frontal-subcortical circuits, 
that are involved in executive functioning, are considered to be disrupted in SIVD. 
But in contrast to patients with VCI, our findings in the HF group also revealed 
extensive memory deficits, that cannot be explained by mild subcortical 
cerebrovascular pathology. Although patients with chronic HF and cardiovascular 
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comorbidity are at risk for cerebrovascular damage, SIVD might therefore not be 
the sole explanation for the observed cognitive changes in HF patients.
Neuroimaging
The comparison of MRI data between the 3 investigated groups, described in 
chapter 3, gave more insight into the above mentioned hypothetical assumptions. 
Our data provides evidence for an higher prevalence of cerebrovascular (WMH, 
lacunar infarcts) and degenerative alterations (MTA) of the cerebrum in patients 
with HF compared to cardiac controls and healthy individuals. MTA, disproportional 
to GCA was an important but unexpected finding in our sample of nondemented 
patients, free of neurological disease. 
Age and hypertension and to a lesser extent diabetes mellitus and atrial fibrillation 
are the most important risk factors for WMH in the general population4;5. These and 
other cardiovascular riskfactors frequently coexist in patients with chronic HF or 
ischemic cardiomyopathy. By use of an age-matched case-control design, 
correcting for common cardiovascular risk factors we found that not the 
cardiovascular risk profile but the decreased heart function itself, represented by a 
low LVEF was independently associated with the presence of WMH in HF patients 
and cardiac controls. The deep cerebral white matter showed a stronger correlation 
to the LVEF than did the periventricular white matter. Furthermore, these cerebral 
WMH were found to be associated with the severity (NYHA-classification) and 
duration of HF.
The second important finding was the higher prevalence of MTA in the HF patient 
group. MTA presumably reflects Alzheimer-type pathology and is mainly 
associated with memory impairment, whereas WMH are of vascular origin and 
have been reported to be associated with poor performance on tasks involving 
executive functions and mental speed. Both MRI-measures are independently 
associated with the severity of clinical dementia6, but the interaction between MTA 
and WMH is inconsistent. Increasing evidence suggests that vascular changes, 
perhaps partly through ischemic injury, may precipitate or exacerbate the 
development of degenerative pathological changes of the brain.7 MTA and 
generalized brain atrophy on MRI are characteristic findings in neurodegenerative 
disease (AD), but are also associated with cardiovascular risk factors and small 
vessel disease. In turn, these cardiovascular risk factors increase the risk of 
cognitive disorders that fulfil criteria of both vascular dementia and AD. Interaction 
between the two types of pathology may be important in producing clinical signs of 
cerebral dysfunction.
MTA rather than WMH predicts cognitive impairment in patients with HF
Degree of WMH has been related to cognitive impairment8, depression9 and 
markedly increased risk of future symptomatic stroke10. Furthermore, the presence 
of confluent WMH at baseline has been shown to be a potent predictor of 
subsequent WMH progression11. A priori, we therefore expected the presence of 
WMH to be associated with cognitive dysfunction in our patient sample. However, 
we found that only MTA was associated with a worse cognitive performance in the 
domains memory and executive functioning. Linear regression analysis revealed 
that this association was independent of other MRI findings and cardiovascular risk 
factors (e.g. hypertension, diabetes mellitus). WMH were significantly associated 
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with both depression and anxiety, whereas no relation was found with the 
neuropsychological outcomes. Perhaps the degree of WMH in our population of 
nondemented, independently living outpatients, was still not severe enough to 
cause overt cognitive dysfunction. 
A probable explanation for the relation between MTA and cognition that has been 
observed among patients with cerebrovascular disease is that these patients are 
more susceptible to developing concomitant AD.12 Another possibility may be that 
these two different pathologies share the same risk factors such as hypertension, 
hypothetically leading to microangiopathy resulting in reduced cerebral blood flow 
to the deep white matter as well as the hippocampus and thereby inducing loss of 
hippocampal neurons13. Damage from recurrent or prolonged hypoperfusion to 
specific brain areas depends on differences in oxygen and glucose requirements of 
individual brain cells and duration of hypoperfusion. The medial temporal lobe 
might be more susceptible to these hemodynamical changes than other cerebral 
structures. Since MTA is thought to be related to memory dysfunction, it could be 
an explanation for the cognitive profile in HF patients, when combined with the VCI 
concept, which is thought to be related to SIVD. This hypothesis is strengthened by 
the finding that a high proportion of vascular dementia cases have Alzheimer 
pathology14, whilst a high proportion of individuals with the neuropathological 
diagnosis of AD have significant cerebrovascular pathological changes15, but 
questions remain in defining the mechanisms of this interaction. 
Considering the recently reported association of HF with an increased risk of AD16
the relation of MTA to the cognitive deficits seen in our sample may be an 
important finding.
Pathophysiological considerations
Chronic cerebral hypoperfusion is thought to represent the main cause of cognitive 
impairment in older patients with HF. However, this thesis has shown that the 
probable underlying pathophysiology is multifactorial, but interpretation of causal 
associations is limited because of our descriptive study design.
One of the other factors frequently discussed is cerebral embolism resulting from 
left ventricular dysfunction and arrhythmias. The cardiogenic stroke risk in patients 
with HF and atrial fibrillation is two- to fourfold in those 50 to 59 year of age 
diminishing to about 1.5 by age 80 to 89 years17. As in atrial fibrillation recurrent 
stroke in cardiac failure is predominantly cardioembolic and, in case of multiple 
microemboli, may lead to vascular dementia18. In patients with HF low left 
ventricular ejection fraction is the most important predictor of risk for cerebral 
infarction and ventricular thrombus formation19;20. Schmidt and colleagues21
suggested in their MRI-study that the territorial type and multiplicity of infarcted 
areas are strongly indicative of an embolic origin for the cerebral damage in a small 
percentage of HF patients. However, our study could not establish a relation 
between cognitive performance and the presence of clinically silent lacunar or 
cortical infarcts. This can partially be explained by the exclusion of patients with a 
history of stroke (n=5 in the HF group, n=3 in the cardiac control group) associated 
with the development of neurological signs or symptoms. It is, however, unlikely 
that this exclusion has led to selection bias. In our population we found no 
significant difference in prevalence of cortical infarcts between the HF patients, the 
cardiac controls and the healthy controls. In contrast, HF patients had more lacunar 
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infarcts than controls, associated with a diagnosis of hypertension. In chapter 6 we 
describe the cerebral blood flow velocity, measured by TCD. During this short-
lasting investigation no emboli, passing the middle cerebral artery, were registered 
by the examiners. Although an appealing hypothesis, cardiogenic cerebral 
embolism is unlikely to be the sole explanation for the observed 
neuropsychological deficits.
On the basis of our data one may speculate that the main cause for the cognitive 
deficits and cerebral abnormalities in patients with chronic HF relates to cerebral 
hypoperfusion. In HF, systolic dysfunction of the heart reduces the left ventricular 
ejection fraction and blood flow to the large cerebral arteries. Several authors22;23
reported regional blood flow reductions in severe HF patients as well as evidence 
for the failure of cerebral auto-regulation. Furthermore, recent evidence supports 
the hypothesis that, in addition to HF, chronic hypotension or excessive 
antihypertensive treatment also pose an increased risk of dementia.16;24 An inverse 
association between systolic blood pressure and the risk of cognitive decline in the 
elderly has been reported in prospective studies24. Our study could only detect this 
association in patients with HF whereas a negative relation was found between 
systolic blood pressure and cognitive performance in healthy controls. Low systolic 
blood pressure levels in HF patients might simply reflect reduced left ventricular 
function, which in turn has been associated with cerebral white matter 
hyperintensities and tends to correlate with cognitive impairment in patients with 
HF. In addition, hypotension, partially due to excessive anti-hypertensive treatment, 
might further reduce cerebral perfusion in the presence of impaired 
cerebrovascular autoregulation22. Our findings of a positive correlation between the 
number of antihypertensive medications used and the severity of WMH in HF 
patients may fit this hypothesis. However, longitudinal studies are needed to 
confirm a causal relation. 
Chapter 6 showed that the CBF-V, measured by TCD was reduced in outpatients 
with HF in comparison to controls, but this reduction was not related to cognitive 
performance or abnormalities of the brain diagnosed by MRI. In contrast to patients 
with advanced stages of HF, our sample of outpatients had relatively mild cerebral 
blood flow reductions. In the early stages of heart disease the effect of left 
ventricular dysfunction may still be compensated by intact cerebral autoregulatory 
mechanisms, and as a consequence may not lead to permanent cerebral 
hypoperfusion that can be detected by TCD. This might have been the reason for 
the absence of an association between MRI-parameters, cognitive performance 
and the CBF-V. Another explanation may be that the assessment of the CBF-V in 
the large cerebral arteries does not reflect the capillary perfusion in the deep white 
matter and the hippocampus, that is thought to be affected by chronic 
hypoperfusion. At this point, TCD seems not a very powerful tool to help identify 
groups of HF patients exposed to a high risk of cognitive decline in the early stage 
of heart disease. More detailed radiological methods (e.g. SPECT) are needed to 
clarify this possible relation further.
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Study strengths and limitations
The strength of our study lies in the detailed neuropsychological and radiological 
investigation of a well-defined sample of HF patients. Moreover, the composition of 
our patient sample is representative of a general outpatient clinic, and does not 
refer to end stage heart disease or hospitalised patients. Secondly, by use of a 
cardiac control group we were able to adjust for common cardiovascular risk 
factors, thereby leaving HF as the major discriminator between patient groups. 
Some methodological issues, however, need to be addressed.
The recruitment of consecutive outpatients from the HF database could have 
introduced selection bias. A relatively high percentage of eligible subjects refused 
informed consent, mainly because of fatigue. These patients may be in a more 
severe stage of heart disease or they were depressed and therefore refused to 
consent. The prevalence of cognitive impairment might as a consequence be even 
higher in a general outpatient population.
The exclusion of participants who refused MR imaging or were claustrophobic also 
decreases the representativeness of this sample. In addition, the bias introduced 
by the inability to include participants with pacemakers may serve to underestimate 
the prevalence of WMH and MTA if the relationship between HF combined with 
cardiovascular risk factors and MRI brain-abnormalities is true, as we contend. 
Second, testing was incomplete for some patients, excluding their data from the 
analysis, thus decreasing sample size and inducing bias. However, missing data 
were equally distributed among groups and were not related to confounding 
variables like disease severity.
Third, the classification of certain neuropsychological tests may be controversial. 
For example, we categorized letter and categorical fluency tests as “Language” 
tasks although these are commonly used to assess executive function. These are 
tests of controlled verbal production thought to not only involve language but also 
retrieval and clustering of semantically related words that require an intact 
semantic network and memory. The initiation and control over these retrieval 
processes, e.g. switching is considered to be part of the executive functions. 
Therefore, failure on the verbal fluency task may, at least partly, be the result of 
dysfunction in executive functions. However other authors have suggested that for 
example the Thurstone Word Fluencv Task (Thurstone & Thurstone,1962), 
subtests of verbal fluency from the Multilingual Aphasia Examination - Revised, 
and performance on word fluency tasks can be used to asses various aspects of 
language function. In frontal and temporal lobe involvement one might predict that 
anterior-based language functions (i.e. word fluency, grammar syntax) may be 
more compromised than functions that are believed to be more posterior-based 
(i.e., auditory and reading comprehension, naming). Although executive functions 
are involved, these tests do require intact language functions. 
Fourth, we realize that analysis of non-parametric data (MTA and GCA-scores)
using parametric statistical tests may have induced statistical bias. However, on 
the basis of visual inspection of the Q-Q plots and histograms the data were 
sufficiently normally distributed after square root transformation to allow for 
parametric testing.
Finally, the difference between statistical and clinical “significance” is an important 
distinction. Unfortunately, the influence of cognitive test performance on the 
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activities of daily living was not examined in our current study as this was not our 
primary aim. 
Despite these limitations, our studies present substantially informative results in an 
outpatient HF population using appropriate controls. These populations are 
undervalued in the current literature, that needs to address this increasingly 
important topic.
Implications for clinical practice
The chronic nature of HF requires patients to be actively involved in the 
management of their disease, including complex medication regimes and lifestyle 
rules. The ability to memorize, retain and utilise information provided to them is 
therefore of crucial importance. The high rate of non-compliance, in particular 
adherence to medication regimes, observed among HF patients may be explained 
by the deficits in memory and executive functions. The results described in this 
thesis suggest that it is these very mental skills that may be lacking in outpatients 
with chronic HF. It is unlikely that in the near future an accurate method of 
determining the neurocognitive profile of an individual in a very short period of time 
will be developed. However some easy to administer tests, like the clock-drawing-
test or the fluency test could give a crude indication of diminished cognitive 
capacities in HF patients visiting an outpatient cardiology clinic.
The clinician (i.e. usually cardiologists) must have knowledge of the cerebral 
complications of chronic HF and must become adept at assessing patients 
cognitive status and its influence on activities of daily living. The prospect that early 
pharmacological intervention may not only improve cardiac function but also delay 
or even reverse the development of cognitive impairment should stimulate research 
efforts to disentangle the underlying pathophysiological mechanisms.
Although our data suggests that a low systolic blood pressure and excessive 
antihypertensive treatment are associated with worse cognitive performance, at the 
present time the data are insufficient to direct research-based interventions among 
general populations of HF patients. Validation of our findings in large 
representative samples is needed to establish a solid foundation for evidence-
based practice.
Recommendations for future research
Systematic data on cognitive status in HF patients is becoming increasingly 
available, but it is clear that there is need for prospective longitudinal studies, with 
serial MRI and experimental models to clarify the pathogenesis of this condition 
further. Special attention should be given to cerebral morphologic abnormalities in 
the various etiologic subgroups of HF patients. Long term follow up of our patients 
might allow conclusions on the predisposition of HF patients to the development of 
white matter hyperintensities, MTA and related cognitive disorders that are 
specifically associated with abnormal hemodynamical conditions. These studies 
should be a priority if interventions designed to prevent or delay the onset of 
cognitive impairments are to be developed. In addition, it is essential to determine 
to what extent, if any, the functional and/or structural alterations described in this 
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thesis are ameliorated with the treatment of HF and restoration of cerebral blood 
flow. 
In general, neuropsychological tests should be used to specify a cognitive profile; 
the assessment of memory and executive functions is indispensable in this regard. 
Simultaneously, future research must address quality of life issues in these patients 
and include spouses or other caregivers in the outcome analysis. 
The optimal care for patients with HF and cognitive impairment awaits further 
research. Perhaps the most intensive investigations, however, should focus on the 
prevention of this end-stage complication of cardiac disease by adequate control of 
hypertension and other vascular risk factors.
CONCLUSIONS
The major conclusions that can be drawn from this thesis are:
1. Patients with chronic HF display a pattern of cognitive impairment that is 
characterized by deficits in memory, executive functions, mental speed and 
language skills.
2. The cognitive impairments worsen with increasing clinical severity of HF
(NYHA-classification).
3. Patients with chronic HF have more cerebral white matter hyperintensities, 
medial temporal lobe artrophy and lacunar infarcts on MRI brain scans, 
compared to cardiac and healthy controls.
4. The presence of cerebral white matter hyperintensities is associated with a 
lower LVEF in patients with cardiac disease, independently of other 
cardiovascular risk factors.
5. In patients with HF, medial temporal lobe atrophy is associated with 
cognitive impairment whereas white matter hyperintensities are associated 
with signs of depression and anxiety.
6. Patients with chronic HF have lower cerebral blood flow velocities, 
compared to control subjects, that in this stage of heart disease are not 
related to the presence of cerebral white matter hyperintensities or 
cognitive deficits.
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SAMENVATTING
Cognitieve stoornissen bij patiënten met chronisch hartfalen.
Hartfalen is een chronische aandoening waarbij het hart door een verminderde 
pompfunctie niet in staat is weefsels en organen van adequate perfusie te 
voorzien. Afhankelijk van de ernst leidt dit tot snelle vermoeidheid en 
kortademigheid bij geringe inspanning. Vaak is er tevens sprake van vochtretentie 
met perifeer en long oedeem tot gevolg. De belangrijkste oorzaak van hartfalen is 
een verminderde hartspierfunctie als gevolg van ischemische cardiomyopathie 
welke meestal ontstaat door coronairlijden of een myocardinfarct, vaak in 
combinatie met langdurig bestaande hypertensie. Maar ook een klepinsufficientie 
leidend tot een gedilateerde cardiomyopathie of ritmestoornissen zoals 
atriumfibrilleren kunnen resulteren in hartfalen. Naast coronaire hartziekten en 
hypertensie spelen andere veel voorkomende aandoeningen zoals diabetes 
mellitus, COPD, roken en ernstig overgewicht een rol bij het optreden van 
hartfalen.
De prevalentie van hartfalen stijgt sterk met de leeftijd maar komt nauwelijks voor 
bij mensen jonger dan 55 jaar. In 2003 hadden in Nederland 178.900 mensen 
hartfalen en werd naar schatting bij bijna 35.400 mensen hartfalen 
gediagnosticeerd. Met de vergrijzing en verbeterde overleving na een 
myocardinfarct is de verwachting dat deze aantallen in de komende jaren alleen 
maar zullen stijgen. Door sommigen wordt hartfalen ook wel de epidemie van de 
toekomst genoemd.
In het algemeen is er bij de behandeling van patiënten met hartfalen weinig 
aandacht voor de mentale toestand van een patiënt, terwijl dit juist in belangrijke 
mate de kwaliteit van leven bepaalt. 
Hoewel veel ouderen klagen over enige vergeetachtigheid vormen cognitieve 
stoornissen geen onderdeel van het normale ouder worden. Milde cognitieve 
stoornissen komen voor bij ongeveer 17% van de mensen ouder dan 65 jaar. 
Dementie wordt gekenmerkt door een achteruitgang van intellectuele (cognitieve) 
functies ten opzichte van het premorbide niveau van functioneren. Onder 
cognitieve functies vallen onder andere het geheugen, waarneming en ruimtelijk 
inzicht, taalvaardigheid, redeneren, logisch denken en het planmatig uitvoeren van 
handelingen. De stoornissen behelzen meestal niet alleen de denkfuncties zelf, 
maar ook het emotionele functioneren en het gedrag. Ze kunnen hierdoor een 
grote invloed hebben op het welbevinden en dagelijks functioneren van patiënten. 
Uiteindelijk kan deze cognitieve achteruitgang leiden tot het klinische syndroom 
dementie, met verlies van onafhankelijkheid en autonomie.  
De laatste decennia wordt hartfalen in toenemende mate erkend als risicofactor 
voor het optreden van cognitieve stoornissen. Verschillende pathofysiologische 
mechanismen zouden bij patiënten met hartfalen bijdragen aan het cognitief 
dysfunctioneren:
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 Cerebrale hypoperfusie
Eerder werd al aangetoond dat een lage linker ventrikel ejectie fractie (LVEF)
van minder dan 40% bij 53% van de patiënten met chronisch hartfalen 
onafhankelijk geassocieerd is met verminderd cognitief functioneren. De 
hiermee samenhangende systolische hypotensie en verminderde cardiale 
output met cerebrale hypoperfusie als gevolg lijkt in voorgaande onderzoeken 
als selectieve cofactor voor het ontstaan van cognitieve dysfunctie 
aangetoond. 
 Micro-embolieën
Naast hypotensie zouden ook cardiale micro-embolieën een  belangrijke  factor 
in het ontstaan van schade kunnen zijn. Systolische dysfunctie van de linker 
ventrikel leidt tot een verhoogd einddiastolsch volume en stasis, waardoor 
cardiale embolieën kunnen ontstaan. Trombus formatie genereert multipele 
micro-embolieën die de cerebrale circulatie verstoren. 
 Cerebrale witte stof afwijkingen
Beeldvorming van de hersenen laat in de oudere populatie frequent witte stof 
afwijkingen zien, waarbij de ernst van de afwijkingen toeneemt met de leeftijd. 
Deze “leucoaraiosis” wordt in de prospectieve studies in verband gebracht met 
lager behaalde scores bij cognitieve functietesten en is significant 
geassocieerd met mentale achteruitgang. Bij het ontstaan van deze witte 
stofveranderingen spelen dezelfde vasculaire risicofactoren een rol als bij het 
ontstaan van hartfalen. Dit betreft dan hypertensie, mogelijk diabetes, roken en 
hypercholesterolemie. Een interessante vraag zou kunnen zijn of de ernst van 
afwijkingen bij MRI onderzoek van de hersenen gerelateerd is aan 
verminderde cerebrale perfusie, meetbaar middels transcranieel doppler 
onderzoek dan wel een gevolg is van het effect van deze vasculaire 
risicofactoren op de vaatwand van de cerebrale vaten. 
De doelstelling van dit proefschrift omvat de volgende aspecten:
1. Inzicht verkrijgen in het neuropsychologisch profiel van poliklinische 
patiënten met chronisch hartfalen. 
2. Het bepalen van klinische en cardiologische parameters die samenhangen 
met de mate van cognitieve stoornissen.
3. Onderzoek naar de bijdrage van hartfalen, naast andere cardiovasculaire 
risicofactoren, aan pathologische veranderingen van de hersenen bij MRI 
onderzoek.
4. Beoordeling van de relatie tussen specifieke MRI afwijkingen van de 
hersenen en stoornissen in de verscheidene cognitieve domeinen.
In hoofdstuk 2 wordt in een systematische review van de beschikbare literatuur de 
relatie tussen het optreden van cognitieve stoornissen en hartfalen geëvalueerd. In 
de afgelopen decennia is er veel onderzoek gedaan naar het voorkomen van 
stoornissen in verschillende cognitieve domeinen bij diverse groepen van patiënten 
met hartfalen. Hieruit komt naar voren dat hartfalen onafhankelijk geassocieerd is 
met stoornissen in het geheugen, de concentratie en de mentale 
verwerkingssnelheid. Echter wordt de interpretatie van de resultaten van deze 
onderzoeken gehinderd door een groot aantal methodologische beperkingen. 
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Allereerst zijn de onderzochte populaties heterogeen van samenstelling. Zo 
worden voornamelijk jonge mannelijk harttransplantatie patiënten onderzocht ofwel 
oudere, gehospitaliseerde, voornamelijk vrouwelijke patiënten in de acute fase van 
het hartfalen. Deze populaties zijn niet representatief voor de dagelijkse 
cardiologische praktijk en bestaan daarnaast uit personen met een diversiteit aan 
co-morbiditeit, zoals cerebrovasculaire aandoeningen en dementie. Een ander 
punt van kritiek is het gebruik van zeer oppervlakkige neuropsychologische testen 
zoals de MMSE (Mini Mental State Examination). Dit is een screenende test die is 
ontwikkeld voor de detectie van Alzheimer dementie en die niet geschikt is voor het 
vaststellen van subtiele cognitieve veranderingen. Met name de zogenaamde 
subcorticale cognitieve stoornissen kunnen worden gemist. Derhalve is het 
mogelijk dat er bij de in de onderzoeken vermelde resultaten sprake is van 
onderdiagnostiek van cognitieve stoornissen. Daarnaast gaan studies die 
uitgebreider neuropsychologisch onderzoek hebben verricht voorbij aan de vraag 
of sprake zou kunnen zijn van een specifiek neuropsychologisch profiel bij 
patiënten met chronisch hartfalen.
Studie opzet.
Zoals hierboven beschreven betreft het grootste methodologische probleem van 
studies naar de invloed van hartfalen op de cognitieve vermogens, de interactie 
tussen cardiovasculaire risicofactoren die zowel bijdragen aan het ontstaan van 
hartfalen, maar hiernaast ook afzonderlijk geassocieerd zijn met het optreden van 
cognitieve stoornissen. 
Gebruik makend van een cross-sectionele, gecontrolleerde studie opzet wilden we 
de bovengenoemde overwegingen inzichtelijk te maken. 
Daartoe hebben we een groep patiënten geïncludeerd van de hartfalen polikliniek
van het St. Lucas-Andreas ziekenhuis met een klinische diagnose van hartfalen 
(NYHA klasse II-IV) en een LVEF van minder dan 40% bij echocardiografisch 
onderzoek. Hiernaast werden patiënten gerecruteerd van de polikliniek cardiologie 
met een ischemische cardiomyopathie en een vergelijkbaar cardiovasculair 
risicoprofiel als de hartfalers echter zonder klinische aanwijzingen voor hartfalen en 
een LVEF van meer dan 40%, de zogenaamde cardiale controles. Alle patiënten 
dienden ouder te zijn dan 50 jaar. Tot slot werd een groep gezonde controle 
personen bestudeerd, zonder relevante medische voorgeschiedenis of afwijkingen 
bij het lichamelijk onderzoek. De exclusiecriteria waren: voorgeschiedenis van een 
CVA, gepaard gaand met neurologische verschijnselen; diagnose van dementie; 
excessief alcoholgebruik; ernstige psychiatrische stoornis of aanwezigheid van een 
depressie; pacemaker implantaat; niet beheersen van de Nederlandse taal;  geen 
informed consent; ernstige anemie (HB<6 mmol/l); gebruik van psychoactieve 
medicatie; en tot slot claustrofobie.
Alle patiënten ondergingen een uitgebreide anamnese, lichamelijk onderzoek, 
bloedonderzoek, neuropsychologisch onderzoek, transcranieel doppler onderzoek 
van de grote hersenvaten en een MRI-scan van de hersenen, volgens een vast 
protocol.
Het neuropsychologisch onderzoek omvatte een grote verscheidenheid aan testen  
die werden ingedeeld in vijf cognitieve domeinen: 1. Geheugen, 2. Executieve 
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functies, 3. Visuospatiële functies, 4. Taal, 5. Mentale snelheid en aandacht. De 
individuele scores op de afzonderlijke neuropsychologische testen werden 
getransformeerd naar z-scores en vervolgens toegewezen aan een domein. 
Hiermee werd het cognitief profiel bepaald. Een totale cognitieve z-score werd 
berekend als indicatie voor de globale cognitieve prestatie van een patiënt. Ook 
werd een MMSE test afgenomen en werden opleidingsniveau (educatie) en 
premorbide intelligentie quotiënt (IQ) gescoord. Factoren die van invloed kunnen 
zijn op de mentale toestand zoals angst en depressie werden eveneens 
geregistreerd.   
In hoofdstuk 3 wordt het cognitief profiel vergeleken van de twee patiënten 
groepen en de gezonde controlegroep. In totaal werden 62 hartfalen patiënten, 53 
cardiale controles en 42 gezonde personen geïncludeerd. De gemiddelde leeftijd 
van de deelnemers was 68,4 en verschilde niet significant tussen de groepen. De 
klinische ernst van het hartfalen varieerde van 2 tot 4 volgens de NYHA-
classificatie, waarbij de meeste patiënten werden ingedeeld in klasse 2, met een 
duur van het hartfalen variërend van 6 maanden tot 15 jaar. Er was geen verschil 
in het cardiovasculair risicoprofiel tussen de twee patiënten groepen behoudens 
een hogere prevalentie van hypercholesterolemie in de cardiale controle groep. 
Conform hun diagnose hadden de hartfalers een lagere LVEF, lagere diastolische 
en systolische bloeddruk dan de controles. 
In vergelijking met de gezonde controles bleken de hartfalers significant slechter te 
presteren op alle cognitieve domeinen, gecorrigeerd voor leeftijd en geslacht. 
Daarentegen presteerden de cardiale controles alleen slechter dan gezonden op 
het domein taal. Hartfalers vertoonden een slechtere totale cognitieve prestatie 
dan cardiale en gezonde controles. De MMSE score, depressie en angst scores 
waren verschilden echter niet significant tussen de 3 groepen. Om een indicatie 
van de prevalentie van cognitieve disfunctie binnen onze hartfalen populatie te 
verkrijgen werd de gemiddelde totale cognitieve z-score van de gezonden min 
twee standaard deviaties gebruikt als afkapwaarde. Alle patiënten die beneden 
deze arbitraire grens presteerden werden beschouwd als cognitief gestoord. Elf 
(25%) van de 44 hartfalers en 5 (15%) van de 34 cardiale controles, tegenover 1 
(4%) van de 26 gezonden werden op deze manier gedefinieerd als cognitief 
gestoord.
Het geschatte IQ, de NYHA klasse en het APOE-4 allel bleken uit een lineaire 
regressie analyse naar voren te komen als onafhankelijke indicatoren voor een 
slechtere totale cognitieve z-score. Hierbij namen de cognitieve stoornissen toe 
met de klinische ernst van het hartfalen, onafhankelijk van de ziekteduur.
Ondanks een nagenoeg gelijk cardiovasculair risicoprofiel blijken patiënten met 
hartfalen slechter te presteren op meerdere cognitieve domeinen dan de cardiale 
controles. Dit maakt waarschijnlijk dat hartfalen als onafhankelijke risicofactor 
bijdraagt aan het voorkomen van cognitieve stoornissen in de onderzochte 
populatie. Executieve functiestoornissen zijn hierbij een belangrijk onderdeel van 
het neuropsychologisch profiel en wellicht een ondergewaardeerd domein in 
voorgaande studies. Verder blijkt dat de MMSE geen geschikte test is voor het 
aantonen van verschillen in subtiele cognitieve stoornissen in de onderzochte 
populatie. Routinematige evaluatie van cognitieve stoornissen bij poliklinische 
patiënten met hartfalen dient onderdeel te zijn van de diagnostiek. Kennis van het 
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cognitief profiel geeft de behandelaar zo de mogelijkheid het vaak complexe 
behandelregime aan te passen aan de individuele capaciteiten van de patiënt.
In hoofdstuk 4 wordt de frequentie en de aard van afwijkingen op een MRI-scan 
van de hersenen vergeleken tussen 58 patiënten met hartfalen, 48 cardiale en 42 
gezonde controles. De MRI-scans werden beoordeeld op  het voorkomen van 
diepe en periventriculaire witte stof afwijkingen (WMH), lacunaire infarcten en 
globale atrofie en atrofie van de medio-temporale kwab (MTA). Vervolgens werd 
bekeken of cardiale factoren en vasculaire risicofactoren geassocieerd waren met 
de bevindingen op de MRI-scan. 
In vergelijking met de controle patiënten hadden de hartfalers significant meer 
WMH, lacunaire infarcten en MTA, gecorrigeerd voor andere vasculaire 
risicofactoren zoals hypertensie en diabetes. Cardiale controles hadden alleen 
meer MTA dan gezonden. Leeftijd en de LVEF waren onafhankelijk geassocieerd 
met de totale WMH score, terwijl leeftijd en systolische hypotensie geassocieerd 
waren met de mate van MTA in de twee patiëntengroepen. Daarnaast waren een 
lagere LVEF en een hoger NYHA klasse beide positief geassocieerd met de mate 
van witte stof afwijkingen van de hersenen. De ernst van het hartfalen lijkt hiermee 
een belangrijke voorspeller voor het optreden van cerebrovasculaire schade (WMH 
en lacunaire infarcten) in de onderzochte populatie. We concludeerden dat 
hartfalen, naast andere cardiovasculaire risicofactoren, een onafhankelijke bijdrage 
zou kunnen leveren aan het voorkomen van WMH en MTA. 
De relatie tussen de gevonden afwijkingen bij MRI onderzoek van de hersenen 
(hoofdstuk 4) en de cognitieve prestatie (hoofdstuk 3) van de patiënten met 
hartfalen wordt beschreven in hoofdstuk 5. Bij 58 hartfalers werden partiele 
correlaties berekend tussen de cognitieve domein scores, de MMSE en WMH, 
MTA en globale corticale atrofie. 
We vonden dat in de onderzochte populatie van poliklinische patiënten met mild tot 
matig hartfalen MTA gecorreleerd was met verminderde cognitieve prestatie, 
bestaand uit geheugenproblemen en executieve functiestoornissen. Lineaire 
regressie analyse, gecorrigeerd voor leeftijd, geslacht, IQ en depressie toonde aan 
dat MTA negatief gecorreleerd was aan de totale cognitieve z-score, onafhankelijk 
van andere MRI-afwijkingen (WMH, globale corticale atrofie) of cardiovasculaire 
risicofactoren (hypertensie, diabetes mellitus, roken, atrium fibrilleren). WMH 
daarentegen, bleek geassocieerd te zijn met symptomen van depressie en angst, 
maar niet met de neuropsychologische test resultaten. Op basis van deze 
resultaten lijkt er een belangrijke rol weggelegd voor atrofie van de mediale 
temporaal kwab bij cognitief gestoorde patiënten met hartfalen, echter is een 
additioneel effect van WMH niet uitgesloten. Het onderliggend pathofysiologisch 
mechanisme blijft onduidelijk, aangezien de lage LVEF bij patiënten met hartfalen 
voornamelijk de diepe witte stof negatief beïnvloedt.  
Hoofdstuk 6 gaat dieper in op de vermeende pathofysiologische mechanismen die 
ten grondslag kunnen liggen aan het optreden van cognitieve stoornissen bij 
patiënten met chronisch hartfalen. Er zijn aanwijzingen dat bij progressief dalende 
cardiale output ook de cerebrale perfusie afneemt. Het hoofdstuk beschrijft de 
relatie tussen cerebrale bloedstroom snelheden (CBF-V), gemeten met 
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transcranieel Doppler onderzoek en de cognitieve maten en MRI-afwijkingen bij 46 
patiënten met hartfalen, 33 cardiale controles en 22 gezonde controles. De CBF-V 
werd gemeten aan de arteria cerebri media beiderzijds. 
Hartfalen patiënten hadden significant lagere CBF-V dan gezonde controles. Er 
werden echter geen associaties gevonden tussen de CBF-V en 
neuropsychologische uitkomsten of MRI-maten. Transcranieel doppler onderzoek 
lijkt derhalve ongeschikt om in dit stadium van hartfalen, patiënten met een 
verhoogd risico op het voorkomen van cognitieve stoornissen of MRI-afwijkingen te 
kunnen identificeren.
Aangezien dit onderzoek descriptief en correlationeel van opzet is, kunnen er geen 
uitspraken worden gedaan over causale verbanden. Longitudinale studie van deze 
populaties is noodzakelijk om meer inzicht te verkrijgen in de ingewikkelde 
onderliggende pathofysiologische mechanismen.
Conclusies die kunnen worden getrokken uit dit proefschrift zijn:
 Patiënten met chronisch hartfalen vertonen in vergelijking met gezonde 
personen cognitieve stoornissen welke worden gekenmerkt door 
geheugenproblemen, executieve functiestoornissen, verminderde 
taalvaardigheid en een beperkte mentale verwerkingssnelheid. 
 De cognitieve stoornissen nemen toe met de klinische ernst van het 
hartfalen (NYHA-classificatie). 
 Patiënten met chronisch hartfalen hebben meer afwijkingen van de witte 
stof, mediale temporaal kwab atrofie en lacunaire infarcten bij MRI 
onderzoek van de hersenen, vergeleken met cardiale controles en 
gezonde personen.
 Het voorkomen van diepe witte stof afwijkingen van de hersenen is, 
onafhankelijk van andere vasculaire risicofactoren, geassocieerd met een 
verminderde LVEF bij patiënten met cardiale ziekte.
 Bij patiënten met hartfalen is mediale temporaal kwab atrofie geassocieerd 
met cognitieve stoornissen en zijn diepe witte stof afwijkingen 
geassocieerd met het voorkomen van depressieve klachten en angst.
 Patiënten met chronisch hartfalen hebben lagere cerebrale bloedstroom 
snelheden die in dit stadium van het hartfalen niet gerelateerd zijn aan het 
voorkomen van witte stof afwijkingen van de hersenen, en evenmin aan 
het optreden van cognitieve stoornissen.
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Dankwoord
Het dankwoord is het meest gelezen hoofdstuk van een proefschrift. Dat is niet 
zonder reden, aangezien dit proefschrift niet voltooid had kunnen worden zonder 
de medewerking van patiënten, vrijwilligers, collega’s, vrienden en andere 
enthousiastelingen. Graag wil ik dan ook iedereen bedanken die heeft bijgedragen 
aan de totstandkoming van dit proefschrift. Naast alle deelnemende patiënten, een 
aantal personen in het bijzonder:
Henry Weinstein, als copromotor een grote stimulans achter de vervoltooiing van 
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